WO2011053247A1 - Method for the detection of an analyte by surface enhanced raman spectroscopy (sers) - Google Patents
Method for the detection of an analyte by surface enhanced raman spectroscopy (sers) Download PDFInfo
- Publication number
- WO2011053247A1 WO2011053247A1 PCT/SG2010/000383 SG2010000383W WO2011053247A1 WO 2011053247 A1 WO2011053247 A1 WO 2011053247A1 SG 2010000383 W SG2010000383 W SG 2010000383W WO 2011053247 A1 WO2011053247 A1 WO 2011053247A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- boronic acid
- benzyl
- biosensor
- bis
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 87
- 238000001514 detection method Methods 0.000 title claims abstract description 52
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 184
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 118
- 239000008103 glucose Substances 0.000 claims abstract description 118
- 239000002105 nanoparticle Substances 0.000 claims abstract description 81
- -1 heteroaryl boronic acid derivatives Chemical class 0.000 claims abstract description 79
- 238000004611 spectroscopical analysis Methods 0.000 claims abstract description 79
- 238000001069 Raman spectroscopy Methods 0.000 claims abstract description 49
- 239000013307 optical fiber Substances 0.000 claims abstract description 13
- 229910052751 metal Inorganic materials 0.000 claims abstract description 10
- 239000002184 metal Substances 0.000 claims abstract description 10
- 150000001543 aryl boronic acids Chemical class 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 94
- 239000000758 substrate Substances 0.000 claims description 89
- 239000010931 gold Substances 0.000 claims description 42
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 39
- 229910052737 gold Inorganic materials 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 150000002772 monosaccharides Chemical class 0.000 claims description 26
- 230000002209 hydrophobic effect Effects 0.000 claims description 25
- 230000003993 interaction Effects 0.000 claims description 25
- 125000005647 linker group Chemical group 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 16
- 125000005620 boronic acid group Chemical group 0.000 claims description 16
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 14
- 229910052709 silver Inorganic materials 0.000 claims description 14
- 239000004332 silver Substances 0.000 claims description 14
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical class OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 13
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 229910000510 noble metal Inorganic materials 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 11
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 11
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- WNWBJAJSYIMGKM-UHFFFAOYSA-N [4-(6-sulfanylidene-3h-purine-9-carbonyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C(=O)N1C(NC=NC2=S)=C2N=C1 WNWBJAJSYIMGKM-UHFFFAOYSA-N 0.000 claims description 8
- 230000009881 electrostatic interaction Effects 0.000 claims description 8
- OFSJRLAMFZVLFG-UHFFFAOYSA-N [3-(6-sulfanylidene-3h-purine-9-carbonyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(=O)N2C3=C(C(N=CN3)=S)N=C2)=C1 OFSJRLAMFZVLFG-UHFFFAOYSA-N 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 7
- MWVTWFVJZLCBMC-UHFFFAOYSA-N 4,4'-bipyridine Chemical group C1=NC=CC(C=2C=CN=CC=2)=C1 MWVTWFVJZLCBMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- LUAZZOXZPVVGSO-UHFFFAOYSA-N Benzyl viologen Chemical class C=1C=C(C=2C=C[N+](CC=3C=CC=CC=3)=CC=2)C=C[N+]=1CC1=CC=CC=C1 LUAZZOXZPVVGSO-UHFFFAOYSA-N 0.000 claims description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 5
- MWEKPLLMFXIZOC-UHFFFAOYSA-N pyren-1-ylboronic acid Chemical compound C1=C2C(B(O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 MWEKPLLMFXIZOC-UHFFFAOYSA-N 0.000 claims description 5
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical class OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- LYXYBFDWMMJOQT-UHFFFAOYSA-N [4-(purine-9-carbonyl)phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C(=O)N1C2=NC=NC=C2N=C1 LYXYBFDWMMJOQT-UHFFFAOYSA-N 0.000 claims description 3
- YNCYPMUJDDXIRH-UHFFFAOYSA-N benzo[b]thiophene-2-boronic acid Chemical compound C1=CC=C2SC(B(O)O)=CC2=C1 YNCYPMUJDDXIRH-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 230000002596 correlated effect Effects 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 114
- 239000000243 solution Substances 0.000 description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000000479 surface-enhanced Raman spectrum Methods 0.000 description 23
- 125000000217 alkyl group Chemical group 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 125000006413 ring segment Chemical group 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 229910052717 sulfur Inorganic materials 0.000 description 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 12
- 239000011521 glass Substances 0.000 description 12
- 239000011593 sulfur Substances 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 101150041968 CDC13 gene Proteins 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 230000004962 physiological condition Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000005110 aryl thio group Chemical group 0.000 description 7
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000000000 cycloalkoxy group Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 7
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 102000035122 glycosylated proteins Human genes 0.000 description 6
- 108091005608 glycosylated proteins Proteins 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- OFDVABAUFQJWEZ-UHFFFAOYSA-N 3-pyridin-3-ylpyridine Chemical compound C1=CN=CC(C=2C=NC=CC=2)=C1 OFDVABAUFQJWEZ-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- MYVJCOQGXCONPE-UHFFFAOYSA-N [2-(bromomethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1CBr MYVJCOQGXCONPE-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000005619 boric acid group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 3
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 3
- YTEIHWVCQJZNEN-UHFFFAOYSA-N 3-pyridin-4-ylpyridine Chemical group C1=CN=CC(C=2C=CN=CC=2)=C1 YTEIHWVCQJZNEN-UHFFFAOYSA-N 0.000 description 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 3
- 0 CCN*1C*C1 Chemical compound CCN*1C*C1 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000007259 addition reaction Methods 0.000 description 3
- 229940061720 alpha hydroxy acid Drugs 0.000 description 3
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 150000003842 bromide salts Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000004953 trihalomethyl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- HBWDWGMBZIFBQE-UHFFFAOYSA-N benzylboronic acid Chemical compound OB(O)CC1=CC=CC=C1 HBWDWGMBZIFBQE-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000012306 spectroscopic technique Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940071240 tetrachloroaurate Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UOQFZGVGGMHGEE-UHFFFAOYSA-N 1,1-dihydroxypropan-2-one Chemical compound CC(=O)C(O)O UOQFZGVGGMHGEE-UHFFFAOYSA-N 0.000 description 1
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- UUEWCQRISZBELL-UHFFFAOYSA-N 3-trimethoxysilylpropane-1-thiol Chemical compound CO[Si](OC)(OC)CCCS UUEWCQRISZBELL-UHFFFAOYSA-N 0.000 description 1
- NZDXSXLYLMHYJA-UHFFFAOYSA-M 4-[(1,3-dimethylimidazol-1-ium-2-yl)diazenyl]-n,n-dimethylaniline;chloride Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1N=NC1=[N+](C)C=CN1C NZDXSXLYLMHYJA-UHFFFAOYSA-M 0.000 description 1
- BDYBZQYAJHFPGM-UHFFFAOYSA-N 5-pyridin-3-ylpyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(C=2C=NC=CC=2)=C1 BDYBZQYAJHFPGM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IBJSOHDOSZDSCT-QNMAEOQASA-N C/C=C(/CBr)\C=C/C=C Chemical compound C/C=C(/CBr)\C=C/C=C IBJSOHDOSZDSCT-QNMAEOQASA-N 0.000 description 1
- 241000252506 Characiformes Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229910004042 HAuCl4 Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000854711 Shinkai Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DUALOHXOIXCERX-UHFFFAOYSA-N [2-(7H-purin-2-yl)phenyl]boronic acid Chemical compound N1=C(N=C2N=CNC2=C1)C1=C(C=CC=C1)B(O)O DUALOHXOIXCERX-UHFFFAOYSA-N 0.000 description 1
- PSENGWOEZLKGJB-UHFFFAOYSA-N [2-(7H-purine-2-carbonyl)-3-sulfanylphenyl]boronic acid Chemical class SC=1C(=C(C=CC=1)B(O)O)C(=O)C1=NC=C2NC=NC2=N1 PSENGWOEZLKGJB-UHFFFAOYSA-N 0.000 description 1
- JTDMUJILHNAXBG-UHFFFAOYSA-N [phenyl-(7H-purin-2-yl)-sulfanylmethyl]boronic acid Chemical class SC(C1=CC=CC=C1)(B(O)O)C1=NC=C2NC=NC2=N1 JTDMUJILHNAXBG-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- DYBXVITUBPGBBW-UHFFFAOYSA-N anthracen-1-ylboronic acid Chemical compound C1=CC=C2C=C3C(B(O)O)=CC=CC3=CC2=C1 DYBXVITUBPGBBW-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000001973 desoxyriboses Chemical class 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UQPHVQVXLPRNCX-UHFFFAOYSA-N erythrulose Chemical compound OCC(O)C(=O)CO UQPHVQVXLPRNCX-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- BUKKGACRIMLXST-UHFFFAOYSA-N ethyl 3-bromo-2H-pyridine-3-carboxylate Chemical compound C(C)OC(C1(CN=CC=C1)Br)=O BUKKGACRIMLXST-UHFFFAOYSA-N 0.000 description 1
- RTHSJMMQOUQNPW-UHFFFAOYSA-N ethyl 5-pyridin-3-ylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=CC(C=2C=NC=CC=2)=C1 RTHSJMMQOUQNPW-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- NICDRCVJGXLKSF-UHFFFAOYSA-N nitric acid;trihydrochloride Chemical compound Cl.Cl.Cl.O[N+]([O-])=O NICDRCVJGXLKSF-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- WJKIGWPCVFLGAT-UHFFFAOYSA-N pyridine;dihydrobromide Chemical class [Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 WJKIGWPCVFLGAT-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000004557 single molecule detection Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
Definitions
- the present invention relates to a method, device and compounds for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS).
- SERS Surface Enhanced Raman Spectroscopy
- a solution to these problems could be a sensor based on reversible binding of glucose to an artificial receptor, such as boronic acid.
- an artificial receptor such as boronic acid.
- ability of boronic acids to bind to glucose reversibly under physiological conditions is well documented in literature.
- a sensing system based on this interaction offers considerable advantages in terms of stability and ease of fabrication.
- a method of glucose sensing with a boronic acid functionalized dye is for example disclosed in US 5,137,883.
- Yoon and Czarnik reported the first scientific study on boronic acid based glucose sensing using anthracenyl boronic acid which produced a measurable change in fluorescent intensity upon binding to glucose in solution (Yoon & Czarnik, J. Am. Chem. Soc. 1992;114:5874-5875).
- Vibrational spectroscopic techniques namely infra red (IR), normal Raman and Surface Enhanced Raman (SER) have been considered for glucose detection. Since near IR and mid IR technique suffers with the limitation of competing absorption from aqueous media, Raman spectroscopic techniques have evolved as the methods of choice. Raman spectroscopy has been used as valuable tool for structural information due to the molecular vibrational finger prints available by the spectrum. However, the applications were limited under biological conditions mainly due to the poor sensitivity and the need for high laser power and complicated instrumentation.
- SERS Surface Enhanced Raman spectroscopy
- the present invention provides for methods, devices and compounds for the sensitive analyte detection using SERS.
- the present invention thus relates to a method for detecting an analyte using surface enhanced Raman spectroscopy (SERS), including contacting the analyte with one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives, wherein the one or more compounds are attached to a metal substrate surface that enhances Raman scattering; and detecting a surface enhanced Raman signal from said compound.
- the surface enhanced Raman signal of the compound is correlated with the amount of the analyte.
- this method is suitable for the detection of the analyte in vivo or, alternatively, the analyte may be contained in a sample and the detection is in vitro.
- analyte is detected in a bodily fluid comprising said analyte.
- this bodily fluid is selected from the group consisting of plasma, serum, blood, lymph, liquor and urine.
- the analyte to be detected is an a-hydroxy acid or a monosaccharide, such as glucose.
- the compound is attached to the substrate surface via electrostatic, hydrophobic or covalent interactions.
- the compound is selected from the group consisting of phenyl boronic acid derivatives, pyridyl boronic acid derivatives and bipyridyl boronic acid derivatives and salts thereof.
- the compound may for example be a boronic acid substituted benzyl viologen or a 3- or 4-(purin-9-ylcarbonyl)phenyl boronic acid or salt thereof.
- the compounds are covalently attached to the substrate surface via a linker.
- the linker comprises at least one thiol group that facilitates binding to the substrate surface.
- the linker may comprise an ethylene glycol of the formula -(0-CH 2 -CH 2 ) protest- , wherein n is an integer from 1 to 10.
- the compound is either positively charged and attached to the substrate surface by electrostatic interactions or the compound is hydrophobic and attached to the substrate surface by hydrophobic interactions.
- the compound can be selected from the group consisting of:
- the substrate used in the claimed method is a nanoparticle.
- the nanoparticle may be coated with, comprise or consist of a noble metal.
- the noble metal is selected from gold and silver.
- the nanoparticle is a nanoparticle coated with a silver film or a citrate-stabilized gold nanoparticle.
- the present invention relates to a biosensor for the detection of an analyte using surface-enhanced Raman spectroscopy, comprising a plurality of nanoparticles, wherein one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives are attached to the nanoparticle surface.
- the biosensor further comprises a substrate, wherein said nanoparticles are adherent to the substrate.
- the biosensor is configured for in vivo and/or in vitro use.
- the analyte detected by the biosensor is an a-hydroxy acid or a monosaccharide, such as glucose.
- the biosensor may be configured for quantitative detection of glucose in a physiological concentration range.
- the one or more compounds of the above biosensor are attached to the substrate surface via electrostatic, hydrophobic or covalent interactions.
- the one or more compounds may be selected from the group consisting of phenyl boronic acid derivatives, pyridyl boronic acid derivatives and bipyridyl boronic acid derivatives or salts thereof, such as boronic acid substituted benzyl viologens or salts thereof.
- the one or more compounds are covalently attached to the substrate surface via an organic linker, such as a linker which comprises at least one thiol group that facilitates binding to the substrate surface.
- the linker comprises an ethylene glycol of the formula -(0-CH 2 -CH 2 ) n -, wherein n is an integer from 1 to 10.
- the one or more compounds of the biosensor are either positively charged and attached to the substrate surface by electrostatic interactions or hydrophobic and attached to the substrate surface by hydrophobic interactions.
- the nanoparticle is coated with, comprising or consisting of a noble metal.
- This noble metal is preferably selected from gold and silver.
- the nanoparticle is coated with a silver film.
- the nanoparticle is a citrate-stabilized gold nanoparticle.
- the present invention relates to compounds of general Formula I
- A is heteroaryl and comprises at least one nitrogen atom
- L2 is a linker selected from the group consisting of a direct bond between A and SH, - C(0)-0-(CH 2 ) q -, -C(0)-S-(CH 2 ) q -, -(CH 2 ) p -, -C(0)-S-(0-CH 2 -CH 2 ) n -, -C(0)-S -(CH 2 - CH 2 -0) n -, -C(0)-S - ⁇ CH 2 -CH 2 -0) rule-(CH 2 ) q - and -C(0)-S -(0-CH 2 -CH 2 ) n -(CH 2 ) q -, wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and q is an integer from 1 to 5;
- B is aryl; and salts thereof. These compounds may have use as Raman receptors for monosaccharides or alpha- hydroxy acids.
- A is selected from the group consisting of purinyl, indolyl, pyridinyl, bipyridyl, pyrimidinyl, azaindolyl, pyrrolyl, pyrazinyl, pyridazinyl, isoindolyl, benzimidazolyl, imidazolyl and indazolyl.
- B is preferably selected from phenyl or naphthyl.
- L is bound to A via the at least one nitrogen atom of the heteroaryl ring.
- L is -C(O)-. In further embodiments, L is -C(O)-, A is purinyl, L2 is a direct bond and B is phenyl. In one embodiment, the compounds are of Formula II:
- L is -(CH 2 ) m -. In some embodiments, L is -(CH 2 ) m -, A is purinyl, L2 is a direct bond and B is phenyl.
- the compound is of Formula III:
- A is bipyridyl
- L is -(CH 2 ) m -
- L2 is -(CH 2 ) P -
- B is phenyl.
- A is 4,4 '-bipyridyl
- L and L2 are bound to A via the nitrogen atoms of the bipyridyl moiety.
- the compound is of Formula IV:
- X " is chloride, bromide, iodide or fluoride.
- the boronic acid substituent is in the m- or p-position of the aromatic (phenyl) ring.
- A is purinyl and the thiol substituent is in the 2- or 6-position of the purine ring.
- the compounds of the invention may be halogen salts, such as the respective bromide salts.
- the compounds are compounds of Formula V
- X " is chloride, bromide, iodide or fluoride
- D is selected from the group consisting of-(CH 2 ) p -, -(0-CH 2 -CH 2 ) n -, -(CH 2 -CH 2 -0) n -, -(CH 2 -CH 2 -0) n -(CH 2 ) m - and -(0-CH 2 -CH 2 ) n -(CH2)m- ) wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and m is an integer from 1 to 5.
- the compound is a compound of Formula VI
- X " is chloride, bromide, iodide or fluoride, and n is an integer from 1 to 10.
- the pyridyl rings are connected such as to form a 3,4'-, 4,3 ? -, 3,3'- or 4,4'-bipyridyl structure.
- the bipyridyl benzyl boronic acid moiety is selected from the group consisting of:
- inventions of the above compounds are the compounds, wherein the -C(O)- S-(CH 2 -CH 2 -0) n -CH 2 -SH or the -C(0)-S-D-SH group is in the m-position relative to the nitrogen atom of the pyridine ring.
- any one or more of the above-mentioned compounds are used.
- the invention relates to the biosensor according to the invention, wherein the biosensor comprises one or more of the above compounds of the invention.
- the present invention also relates to an optical fiber comprising a biosensor according to the invention.
- the present invention features the use of any one of the above- mentioned compounds as a monosaccharide, in particular glucose, or a-hydroxy acid receptor.
- the present invention relates to the use of the biosensor or the optical fiber according to the invention for the detection of an analyte.
- the detection is in vivo. In another embodiment the detection is in vitro.
- the analyte is a monosaccharide, such as glucose, or an a-hydroxy acid.
- Figure 1 shows a schematic representation of the major components of the SERS based analyte sensing system using reporter molecules.
- the exemplary analyte referred to in the figure is glucose, but the claimed invention is not limited thereto.
- the reporter molecule can attach to the nanoparticle by electrostatic, covalent or hydrophobic interactions and upon glucose binding change the intensity or position of SERS signals. These changes can be monitored as glucose sensing event at the molecular level.
- Figure 2 shows the proposed mechanism of analyte/glucose detection by SERS using a benzyl viologen as a reporter molecule and a gold nanoparticle as the SERS active surface.
- FIG. 3 shows UV studies of benzyl viologen boronic acids with 40 run gold nanoparticles.
- BBV1 has a X max at 259.5 nm and an Au nanoparticle has a max at 527 nm.
- the aggregation leads to the shift of the plasmon peak to 752 nm.
- Figure 4 schematically shows the manufacturing protocol for a glucose sensing substrate (a).
- Figure 4 (b) shows the Emission Scanning Electron Microscopy (ESEM) characterization of the morphology of the glucose sensing substrate, and
- Figure 4 (c) shows SERS spectrum of BVB1 on the glucose sensing substrate.
- Figure 4 d) shows a Raman spectrum of BBV1 in powder form for comparison.
- Figure 5 shows the response of the SERS spectrum of BBV1 upon glucose binding under physiologically relevant conditions. The actual base line is shifted from zero for clarity reasons.
- Figure 6 shows the response of the four major SERS peaks of BBV1 on novel glucose sensing substrates upon glucose binding under physiological conditions.
- Figure 7 shows the glucose responsiveness of the SERS peak of BBV1 under physiological conditions under different BBV1 concentrations: a) Glucose response from SERS substrate incubated with 1 ⁇ BBV1 (left graph), b) Glucose response from the SERS substrate incubated with 1 mM BBV1 (right graph).
- Figure 8 shows the chemical structures of benzyl viologen control compounds. The lack of glucose receptive boronic acid moieties makes them unresponsive to glucose.
- Figure 9 shows the chemical structures of all possible isomers of BBV1 that are synthesized and characterized with 4,4'-; 3,3'- and 4,3'- bipyridine moieties as the SERS reporting core.
- Figure 10 shows the SERS spectrum of the all possible isomers of BBV1 that were synthesized to evaluate the glucose sensibility and glucose selectivity of this class of Raman reporter molecules.
- Figure 11 shows the glucose response of 3,4'-o-BBV SERS spectrum peak at 1620 cm- 1.
- Figure 12 shows representative examples of boronic acid derivatives that can be immobilized by hydrophobic interaction on gold nanoparticles for glucose sensing using SERS mode in solution.
- Figure 13 shows the SERS spectrum of a) thionaphthene boronic acid and b) pyrene boronic acid in milliQ water after mixing with 40 nm citrate stabilized gold nanoparticles.
- Figure 14 shows glucose response from thionaphthene boronic acid immobilized gold nanoparticles.
- Figure 15 shows the SERS spectrum of 4-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid (A) and 3-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid (B) covalently anchored via their mercapto groups on the surface on the produced SERS substrate.
- Figure 16 shows the glucose response of 4-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid by determining the SERS intensity of the peak at 1001 cm "1 in a flow cell experiment where glucose concentration was systematically varied.
- Figure 17 schematically shows an exemplary design of an optical fiber coupled to a biosensor according to the present invention.
- This invention relates to a novel method, device and compounds for detecting an analyte, specifically an analyte with poor Raman cross section, using Surface Enhanced Raman Spectroscopy (SERS).
- SERS Surface Enhanced Raman Spectroscopy
- the present invention relates to a method for detecting an analyte using surface enhanced Raman spectroscopy (SERS), comprising contacting the analyte with one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives, wherein the one or more compounds are attached to a metal substrate surface that enhances Raman scattering; and detecting a surface enhanced Raman signal from said compound.
- SERS surface enhanced Raman spectroscopy
- the compounds used in this method are Raman reporters, i.e. compounds which have a high Raman cross section and the Raman vibrational "finger print" is detectably altered, for example by a shift and/or an increase in intensity, upon the binding an analyte, such as to allow detection and quantitation of the analyte.
- the compounds can also be considered to represent reporters or receptors of the analyte, for example glucose reporters or receptors.
- the compounds can be stably adsorbed at a surface that enhances the Raman signal from the compound, such as a nanoparticle or other SERS active substrate surface by reversible electrostatic interaction, hydrophobic interaction or covalent anchoring.
- the compound has a high Raman cross section and the capability to adsorb strongly on the surface of a metal nanoparticle in aqueous media so that it gives a fast and intense and non fluctuating SERS signal that is proportional to the concentration of the analyte, such as glucose, in bulk.
- SERS using Raman reporters is advantageous over the prior art glucose oxidase based systems as it is independent of oxygen.
- the methods according to the invention allow the detection of analytes in lower concentration ranges, such as glucose in hypoglycemic concentration range, and thus provide a more reliable readout in the analysis of patients.
- the detection range can be suitably adjusted to the desired analyte concentration range thus ensuring a linear measurement range.
- a further advantage of the receptors of the present invention is that they selectively, reversibly and covalently bind to the analyte; stably enough to allow a strong SERS mediated analyte detection and reversible in order to avoid a permanent loss of analyte binding sites and analyte.
- the Raman reporter selectively binds to the analyte, a more specific readout is accomplished.
- the Raman reporters are adsorbed at biocompatible substrates, such as noble metals, they can detect the desired analyte under physiological conditions, meaning that the sensing components can be integrated in a minimally invasive platform, such as optical fibers or implantable substrates.
- the substrates of the present invention bind the Raman reporters but bind other molecules to a very low extent and thus provide a longer lasting setup, in particular in an implanted biosensor setup.
- the methods of the invention do not rely on fluorescence, they overcome previous limitations of methods based on fluorescent dyes or Quantum dots, as they are not hampered by photo bleaching, broad emission profiles and peak overlapping.
- the SERS-based detection methods of the invention are suitable for multiplexing, which is another advantage, both in context of sensing experiments to understand complex mechanistic pathways in biological studies and in personalized medicine.
- aryl boronic acids Usually, in absence of analyte, these receptors exist in their trigonal neutral form.
- the formation of the more-acidic boronate-analyte complex shifts the acid-base equilibrium of the boronic acid towards its anionic tetrahedral "-ate" form, causing electronic and/or steric changes.
- This change in molecular structure causes a significant change in the orientation and distance of the molecule from the nanoparticle surface leading to a change in the SERS intensity of the molecular core.
- the compounds according to the invention are aryl or heteroaryl boronic acid derivatives or aryl or heteroaryl boronate derivatives.
- aryl boronic acid or “aryl boronate” relates to organoboranes with a carbon boron bond, wherein a boric acid or salt or ester thereof is substituted with an aryl moiety.
- These compounds have the general structure R-B(OH) 2 , wherein R is the aryl moiety.
- R is the aryl moiety.
- the hydrogen atoms may be replaced by organic residues or suitable cations.
- the aryl moieties of the present invention preferably comprise 5-20 carbon atoms and can comprise 1-5 rings, which are either condensed or connected by bonds.
- aryl moieties include, but are not limited to phenyl, naphthyl, pyrenyl and anthracenyl. Preferred are phenyl moieties, thus forming phenyl boronic acids.
- heteroaryl boronic acid and “heteroaryl boronate” relates to organoboranes with a carbon boron bond, wherein a boric acid or salt or ester thereof is substituted with a heteroaryl moiety.
- R-B(OH) 2 wherein R is the heteroaryl moiety.
- the hydrogen atoms may be replaced by organic residues or suitable cations.
- heteroaryl moieties of the present invention preferably comprise 5-20 carbon atoms and can comprise 1-5 rings, which are either condensed or connected by bonds, wherein at least one of the ring carbon atoms is replaced by nitrogen, oxygen or sulfur.
- heteroaryl moieties according to the invention include, but are not limited to purinyl, indolyl, pyridinyl, bipyridyl, pyrimidinyl, azaindolyl, pyrrolyl, pyrazinyl, pyridazinyl, isoindolyl, benzimidazolyl, imidazolyl, indazolyl, chinolinyl, isochinolinyl, acridinyl and benzothiophenyl.
- the term "derivatives" in relation to the compounds of the present invention means that the aryl/heteroaryl boronic acid/boronate structure can be substituted with further substituents or groups and can thus be part of a larger molecule.
- the substituents are one or more, preferably 1-5 groups, selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalicyclic, alkoxy, cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, hydroxy, halo, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NR'R 2 where R 1 and R 2 are independently selected
- Alkyl refers to a saturated aliphatic hydrocarbon including straight chain, or branched chain groups.
- the alkyl group has 1 to 10 carbon atoms (whenever a numerical range; e.g.,"l-10", is stated herein, it means that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 10 carbon atoms). More specifically, it may be a medium size alkyl having 1 to 6 carbon atoms or a lower alkyl having 1 to 4 carbon atoms e.
- alkyl group may be substituted or unsubstituted.
- the substituent group(s) is one or more, for example one or two groups, individually selected from the group consisting of C 3 -C 3 ⁇ 4 cycloalkyl, C 6 -C 14 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicychc wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, C Cjo alkoxy, C 3 -C 8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NR J R 2 where R and R are independently selected from the group consisting of hydrogen, Ci- C 4 alkyl, C 3 -Cg cycloalkyl
- a "cycloalkyl” group refers to an all-carbon monocyclic ring (i.e., rings which share an adjacent pair of carbon atoms) of 3 to 8 ring atoms wherein one of more of the rings does not have a completely conjugated pi-electron system e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like.
- cycloalkyl groups examples, without limitation, are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, adamantane, cyclohexadiene, cycloheptane and, cycloheptatriene.
- a cycloalkyl group may be substituted or unsubstituted.
- the substituent group(s) is one or more, for example one or two groups, individually selected from Ci-Cio alkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicychc wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Ci-Cio alkoxy, C 3 -C 8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NR'R 2 , with R 1 and R 2 as defined above.
- alkenyl refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon double bond e. g., ethenyl, propenyl, butenyl or pentenyl and their structural isomeric forms such as 1-or 2-propenyl, 1-, 2-, or 3-butenyl and the like.
- alkynyl refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon triple bond e.
- aryl group refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups of 6 to 14 ring atoms and having a completely conjugated pi- electron system. Examples, without limitation, of aryl groups are phenyl, naphthenyl and anthracenyl. The aryl group may be substituted or unsubstituted.
- the substituted group(s) is one or more, for example one, two, or three substituents, independently selected from the group consisting of Q-Cio alkyl, C3-C8 cycloalkyl, C 6 - Ci 4 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicyclic wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Q-Cio alkoxy, C 3 -Cg cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, trihalomethyl, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NR'R 2 , with R 1 and R 2 as defined above.
- heteroaryl group refers to a monocyclic or fused aromatic ring (i.e., rings which share an adjacent pair of atoms) of 5 to 10 ring atoms in which one, two, three or four ring atoms are selected from the group consisting of nitrogen, oxygen and sulfur and the rest being carbon.
- heteroaryl groups are pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,3,4- triazinyl, 1 ,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolizin
- the heteroaryl group may be substituted or unsubstituted.
- the substituted group(s) is one or more, for example one or two substituents, independently selected from the group consisting of Ci-C )0 alkyl, C 3 -C 8 cycloalkyl, C 6 - C 14 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicyclic wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Ci-C] 0 alkoxy, C 3 -C 8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, trihalomethyl, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino,
- heteroaryl if heteroaryl is pyridyl, the substituent is pyridyl to give bipyridyl.
- a "heteroalicyclic" group refers to a monocyclic or fused ring of 5 to 10 ring atoms containing one, two, or three heteroatoms in the ring which are selected from the group consisting of nitrogen, oxygen and -S(0) fashion where n is 0-2, the remaining ring atoms being carbon.
- the rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system.
- heteroalicyclic groups examples, without limitation, of heteroalicyclic groups are pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, tetrahydropyridazine, tetrahydrofuran, thiomorpholine, tetrahydropyridine, and the like.
- the heteroalicyclic ring may be substituted or unsubstituted.
- the substituted group (s) is one or more, for example one, two, or three substituents, independently selected from the group consisting of Q- Cio alkyl, C 3 -C 8 cycloalkyl, C 6 -Ci 4 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicyclic wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Q-Cio alkoxy, C 3 -C 8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, trihalomethyl, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitrb, silyl, sulfinyl, sulfonyl, amino, and -NR'R 2 , with R 1 and R 2 as defined above.
- a "hydroxy” group refers to an -OH group.
- alkoxy refers to an -O-unsubstituted alkyl and -O-substituted alkyl group, as defined herein. Examples include and are not limited to methoxy, ethoxy, propoxy, butoxy, and the like.
- a "cycloalkoxy” group refers to a -O-cycloalkyl group, as defined herein. One example is cyclopropyloxy.
- aryloxy refers to both an -O-aryl and an -O-heteroaryl group, as defined herein. Examples include and are not limited to phenoxy, naphthyloxy, pyridyloxy, furanyloxy, and the like.
- a “mercapto” group refers to a -SH group.
- An “alkylthio” group refers to both an S-alkyl and an -S-cycloalkyl group, as defined herein. Examples include and are not limited to methylthio, ethylthio, and the like.
- arylthio refers to both an -S-aryl and an -S-heteroaryl group, as defined herein. Examples include and are not limited to phenylthio, naphthylthio, pyridylthio, furanylthio, and the like.
- a “sulfinyl” group refers to a -S(0)-R' group, wherein, R' is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, ar; yl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), as defined herein.
- a “sulfonyl” group refers to a -S(0) 2 R' group wherein, R' is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), as defined herein.
- a “trihalomethyi” group refers to a -CX 3 group wherein X is a halo group as defined herein e. g., trifluoromethyl, trichloromethyl, tribromomethyl, dichlorofluoromethyl, and the like.
- Representative examples include and the not limited to acetyl, propionyl, benzoyl, formyl, cyclopropylcarbonyl, pyridinylcarbonyl, pyrrolidin-l-ylcarbonyl, and the like.
- R as defined herein, e. g. -COOH, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, and the like.
- a “carboxylic acid” group refers to a C-carboxy group in which R' is hydrogen.
- halo or halogen group refers to fluorine, chlorine, bromine or iodine.
- a "cyano" group refers to a -CN group.
- a "nitro” group refers to a -N0 2 group.
- amino group refers to an -NR'R 2 group, wherein R 1 and R 2 are independently hydrogen or unsubstituted lower alkyl, e.g., -NH 2 , dimethylamino, diethylamino, ethylamino, methylamino, and the like.
- the term "detection”, as used herein, refers to the identification of the presence or absence of an analyte and/or quantifying its amount.
- the analyte can be detected in a concentration range of mM, below mM, below ⁇ , below nM, below pM, below fM or at a single molecule level.
- Surface Enhanced Raman Spectroscopy, or Surface Enhanced Raman Scattering, abbreviated SERS is a surface sensitive technique that results in the enhancement of Raman scattering by molecules adsorbed on metal surfaces.
- the enhancement factor can be as much as 10 I4 -10 15 , which allows the technique to be sensitive enough to detect single molecules.
- Substrates suitable in the present invention comprise nanoparticles, in particular nanoparticles made of materials or coated with materials which enhance the Raman signal of a substrate-attached compound.
- materials that are capable of enhancing the Raman signal of a compound attached thereto are noble metals, such as copper, silver or gold.
- the nanoparticles may be made of plastic, ceramics, composites, glass or organic polymers and coated with the metal of choice, such as silver or gold.
- the nanoparticles may be made of a metal, for example a noble metal, such as silver or gold. Methods for the production of nanoparticles are well-known in the art and include sol-gel processes.
- the nanoparticles may have a medium diameter of about 1 to about 100 nm, such as 10, 20, 30, 40, 50, 60, 70, 80, or 90 nm. If gold nanoparticles are used, these may be stabilized, for example by citrate.
- the nanoparticles may be located on a surface and/or attached or adhered thereto. Alternatively, the surface may be an electrochemically roughened silver surface.
- the compounds, i.e. the Raman receptors, which are attached to the substrate can be covalently bound, attached via electrostatic attraction or hydrophobic interaction.
- Covalently bound relates to an attachment on the surface via a covalent bond between at least one atom of the compound and at least one atom of the surface.
- Electrostatic attraction relates to attachment via salt bridges, hydrogen bonds and polar interactions, for example if the surface is charged negative and the compound bears a positive charge or vice versa.
- Hydrophobic interaction includes the interaction between uncharged and non-polar groups.
- the surface enhanced Raman signal of the compound can be correlated with the amount of the analyte in the sample.
- “Correlation” means that the change of the SERS signal due to the binding of the analyte depends on the amount of the analyte. This correlation allows quantifying the amount of analyte.
- the change of the SERS signal may be a change in intensity of certain bands and/or a shift in the peak wave numbers.
- the method is suitable for the detection of an analyte in vivo, as the structures necessary for carrying out the method can be implemented on a biosensor.
- the analyte may be contained in a sample and the detection is in vitro.
- the method according to the invention allows detection of the analyte in a bodily fluid.
- This bodily fluid may be selected from the group consisting of plasma, serum, blood, lymph, liquor and urine.
- the analyte to be detected according to the invented method is a monosaccharide or an a-hydroxy acid.
- the monosaccharide may be an aldose or ketose and can be selected from the group consisting of trioses, tetroses, pentoses, hexoses and heptoses.
- Exemplary monosaccharides include, but are not limited to, glucose, galactose, fructose, mannose, glyceraldehyde, dihydroxyaceton, erythrose, threose, erythrulose, ribose, arabinose, xylose, desoxyribose, ribulose, xylulose, and talose.
- sugar alcohols such as mannitol and sorbitol
- sugar acids such as glucuronic acid and galacturonic acid
- derivatives of monosaccharides such as N-Acetyl-D-glucosamine and glucosamine.
- the term includes all stereoisomers, in particular the D- and the L-form and the a- and ⁇ -configuration.
- Exemplary monosaccharides include, but are not limited to: a-D-glucose, ⁇ -D-glucose, a-D-galactose and ⁇ -D-galactose.
- the monosaccharide to be detected is glucose, more preferably D-glucose, even more preferably a-D-glucose.
- a-hydroxy acids including, but not limited to, glycolic acid, lactic acid, citric acid, mandelic acid, malic acid and isocitric acid.
- the analyte may be free in solution, either in a cell or in a bodily liquid.
- the analyte may be attached to another substance, including proteins, lipids, DNA, RNA and cells.
- the analyte may be attached to a protein, in case the analyte is a monosaccharide thus forming a glycosylated protein.
- Glycosylated proteins typically comprise the following monosaccharides: N-acetyl glucosamine, mannose, fructose and galactose. By detecting these saccharides, the method of the invention also allows to detect glycosylated proteins.
- the glycosylated protein may be located at the outer surface of a cell or be present in a bodily fluid.
- Some analytes, such as monosaccharides, in particular glucose, a-hydroxy acids or glycosylated proteins are more or less abundant in a patient with a certain disease, disorder or physical state and are thus indicators of the disease, disorder or physical state. Exemplary diseases include, but are not limited to diabetes, obesity, inflammation and cancer.
- Exemplary physical states include, but are not limited to hypo- and hyperglycemia.
- the methods of the invention allow monitoring an analyte which is an indicator and/or marker of these diseases/physical states in a patient.
- the methods allow diagnosing these diseases, disorders and physical states and establishing a prognosis.
- the amount of glucose detected in a patient or in a patients sample may serve as an indicator of diabetes, hyper- or hypoglycemia.
- the method allows monitoring the treatment of a disease using the amount of analyte as an indicator. In patients suffering from diabetes the amount of detected analyte may indicate the need of an insulin treatment or confirm the efficiency of the insulin treatment.
- analyte such as a glycosylated protein
- detection of an increased or decreased level of a specific analyte, such as a glycosylated protein may be useful for diagnostic purpose.
- a specific analyte such as a glycosylated protein
- One analyte suitable for the diagnosis of prostate cancer includes the serum glycoprotein prostate-specific antigen.
- a patient as defined herein, is an animal, including mammals, in particular a human being.
- the substrate with the attached Raman reporter compounds may also be integrated into cells.
- the method of the present invention also allows detecting an intracellular analyte.
- the SERS signal of the compound may be generated by a laser pointing to the cell, fluorescence microscope, a confocal microscope, or an optical fiber reaching to the cell.
- a confocal microscope may generate the SERS signal in a defined cell compartment.
- the analyte may be detected in a particular cell compartment. Deviation from the analyte level under control conditions may allow drawing conclusions about the state of the cell. Low or high glucose levels may indicate cell stress, in particular oxidative stress.
- the detected analyte may serve as an indicator of apoptosis.
- Cell compartments comprise the cell membrane, the cytoplasm, the ER, the Golgi apparatus, lysosomes, the nucleus, endosomes, lysosomes, mitochondria, chloroplasts and vacuoles.
- the method may be used in a FACS-based cell sorting assay.
- Cells comprising the analyte or cells with a certain level of analyte may be separated from each other into different vessels.
- the transfer of substrates comprising Raman receptors into cells may be achieved by coupling to antibodies, liposome based transfection agents, coupling to or co- administration with protein transduction domains, co-administration with pore- forming agents, endocytosis, or electroporation.
- the compound, i.e. the Raman receptor, to be used in the method is attached to the substrate surface via electrostatic, hydrophobic or covalent interactions.
- the compound is a phenyl boronic acid derivative, pyridyl boronic acid derivative or a bipyridyl boronic acid derivative.
- the compound is a phenyl boronic acid derivative, i.e. a compound including a phenyl ring substituted with a boric acid group.
- the compound also includes a heteroaryl group coupled either directly or via a linker group to the phenyl boronic acid.
- the compound is a boronic acid substituted benzyl viologen, for example a bis(phenyl boronic acid) viologen, or a purinyl phenyl boronic acid, such as a 3- or 4-(purin-9-ylcarbonyl)phenyl boronic acid.
- "Viologen” in this context relates to a bipyridinium core structure, wherein the pyridinium rings are coupled to each other by a 3,3'-, 3,4'- or 4,4'- bond.
- the compounds can include a linker group.
- a preferred linker group is a linker comprising a thiol (-SH) group.
- the thiol group may facilitate covalent attachment to the metal surface by forming a covalent bond between the sulfur atom and a metal surface atom.
- thiol group and mercapto group are used interchangeably herein and both relate to the -SH group.
- the linker may comprise an alkenyl or ethylene glycol chain, for example an ethylene glycol of the formula -(O- CH 2 -CH 2 ) n - , wherein n is an integer from 1 to 10, or an alkenyl group of formula - (CH 2 ) P -, wherein p is an integer from 1 to 20.
- the compound is positively or negatively charged and attached to the substrate surface by electrostatic interactions or the compound is hydrophobic and attached to the substrate surface by hydrophobic interactions.
- the compounds undergoing electrostatic interaction with the substrate may have a bipyridinium core due to its intense SERS response and the ease of functionalization by alkyl halides via quarternization to form a viologen.
- Boronic acid substituted benzyl viologens (See Figures 2 and 10) are particularly useful as SERS reporters for monosaccharide, in particular glucose, detection. SERS signal modulation occurs when the analyte binds to the boronic acid receptor moiety, which at pH 7.4 and in the absence of glucose exists in its trigonal neutral form.
- the SERS substrate based approach is easy to transfer into a fiber mode and allows to reduce toxicity issues due to the use of noble metal based, e.g. gold based, substrates (compared to the toxic fluorescent quantum dot based approach) that can be incorporated into a minimally invasive implantable device.
- the multiplexing capability of SERS provides another advantage both, in context of sensing experiments to understand complex mechanistic pathways in biological studies and personalized medicine.
- BBV1 benzyl boronic acid viologen
- SERS substrate that is fabricated with citrate stabilized gold nanoparticles (cf. Figure 2). Since the gold nanoparticle surface is negatively charged, the positively charged BBV1 can strongly adsorb on the substrate to due to electrostatic interactions. Moreover, the boronic acids groups in BBV1 can form a boronate complex with the citrate leading to the immobilization of the BBV1 molecule on the surface which provides a strong SERS signal upon laser excitation.
- analyte e.g.
- the analyte-receptor complex can produce an increase in SERS intensity due to the steric and electronic changes that follow the binding event.
- the negative charge associated with the boronate complex that forms upon glucose binding to BBV1 leads to a change of the orientation of the molecule relative to the surface leading to a higher SERS signal.
- BB VI compared to the SERS active compound crystal violet, induces much smaller variations of the signal intensity on the substrate, probably due to the symmetric bis positive charge and the bis boronic acid groups that bind tightly on the surface of gold nanoparticle, leading to a more thermodynamically stable surface complex.
- the compounds of the present invention allow for more accurate analyte detection due to smaller signal variations.
- Compounds useful as Raman reports in the invented methods include, but are not limited to:
- N,N'-Bis-(benzyl-3-boronic acid)-[3,3']bipyridinium Dibromide (5,3 -w-BBV);
- Benzothiophene-2-boronic acid Depending on whether the above bipyridinium, pyrene and benzothiophene compounds are to be attached by covalent bonds or not, they may comprise an additional linker group as defined above, which, in case of the viologen compounds, may be attached to the bipyridinium core.
- the bipyridinium compounds can be used as other salts not limited to the bromide salt, such as, for example, other halogen salts like fluoride, chloride or iodide salts.
- the purinyl compounds lack the mercapto group and are attached to the substrate by another linker group as defined above or by electrostatic or hydrophobic interactions.
- the present invention relates to a biosensor for the detection of an analyte using surface-enhanced Raman spectroscopy, comprising a plurality of nanoparticles, wherein one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives are attached to the nanoparticle surface.
- the nanoparticles, the compounds or both can be as defined above in connection with the methods of the invention.
- the analytes to be detected can be the same as those that have been defined above.
- the analytes include monosaccharides, such as glucose, and alpha-hydroxy acids.
- the biosensor is configured for quantitative detection of glucose in a physiological concentration range.
- the biosensor can comprise a substrate to which the nanoparticles are adhered. Adherence may be achieved by any means, including covalent bonding, electrostatic or hydrophobic interactions.
- the attachment of the nanoparticles to the sensor surface may have the form of a coating, including a uniform coating or in form of spots.
- the biosensor is configured for in vivo and/or in vitro use.
- the present invention relates to compounds that are of use as Raman reporters for certain analytes and are thus useful in the methods of the invention.
- the compounds contemplated by the present invention are compounds of general Formula I
- A is heteroaryl and comprises at least one nitrogen atom
- L2 is a linker selected from the group consisting of a direct bond between A and SH, - C(0)-0-(CH 2 ) q -, -C(0)-S-(CH 2 ) q -, -(CH 2 ) p -, -C(0)-S-(0-CH 2 -CH 2 ) n -, -C(0)-S -(CH 2 - CH 2 -0) n -, -C(0)-S -(CH 2 -CH 2 -0) rule-(CH 2 ) q - and -C(0)-S -(0-CH 2 -CH 2 ) n -(CH 2 ) q -, wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and q is an integer
- B is aryl
- the salts of the compounds of the invention include all possible salts, in particular halogen salts. If the compounds comprise quaternary nitrogen atoms, the anion may be selected from fluoride, chloride, bromide and iodide, preferably bromide.
- A comprises at least 1, at least 2, 3, 4 or more nitrogen atoms. Also contemplated is that A is an heteroaryl group consisting of two or more aromatic rings that may be condensed or directly coupled to each other. In various embodiments of the invention, A is selected from the group consisting of purinyl, indolyl, pyridinyl, bipyridyl, pyrimidinyl, azaindolyl, pyrrolyl, pyrazinyl, pyridazinyl, isoindolyl, benzimidazolyl, imidazolyl, indazolyl, chinolinyl, isochinolinyl, acridinyl and benzothiophenyl.
- A is selected from the group consisting of pyridinyl, bipyridinyl and purinyl.
- B can be any aryl group, including aryl groups consisting of 1, 2 or more rings that can either be condensed or covalently coupled.
- B is selected from phenyl or naphthyl, preferably phenyl.
- L is carbonyl -C(O)-.
- A is purinyl
- L2 is a direct bond
- B is phenyl, thus forming mercaptopurinylcarbonyl phenyl boronic acids or salts thereof.
- L2 is -(CH 2 ) P -.
- the compounds are of Formula II:
- the boric acid group can be in the o-, m- or p-position relative to the carbonyl group, preferably in the m- or p-position.
- the mercapto group can be in the 2-, 6- or 8-position of the purinyl ring, preferably in the 2- or 6-position.
- L is -(CH 2 ) m -.
- A can be purinyl
- L2 can be a direct bond
- B can be phenyl, thus forming mercaptopurinyl benzyl boronic acids or salts thereof.
- L2 is -(CH 2 ) P -.
- the compounds are of Formula III:
- the boric acid group can be in the o-, m- or p- position relative to the carbonyl group, preferably in the m- or p-position.
- the mercapto group can be in the 2-, 6- or 8-position of the purinyl ring, preferably in the 2- or 6- position.
- A is bipyridyl
- L is -(CH 2 ) m -
- L2 is -(CH 2 ) P -
- B is phenyl.
- salts of these compounds in particular halogen salts, preferably bromide salts.
- A is bipyridyl, wherein both nitrogens are in the quaternary state, L is - (CH 2 ) m -, L2 is -(CH 2 ) p -, B is phenyl and the compound is a halogen salt. More preferably, the compound is of formula IV:
- the boric acid substituent may be in the m- or p-position of the phenyl ring.
- the invention relates to compounds of Formula V:
- the compound is a compound of Formula VI
- X " is chloride, bromide, iodide or fluoride and n is an integer from 1 to 10.
- the pyridyl rings can be connected such as to form a 3,4'-, 4,3'-, 3,3 '- or 4,4'-bipyridyl structure.
- the bipyridyl benzyl boronic acid moiety may be selected from the group consisting of:
- Further preferred embodiments of these compounds are the compounds, wherein the -C(0)-S-(CH 2 -CH 2 -0) complicat-CH 2 -SH or the -C(0)-S-D-SH group is in the m-position relative to the nitrogen atom of the pyridine ring.
- All the above compounds of the invention are useful as Raman reporters in the SERS technique, in particular the SERS-based detection methods of the invention.
- the present invention also covers the above-described methods of the invention, wherein the compounds used in these methods for analyte binding and detection are those defined above, i.e. the compounds of the invention.
- the compounds used as Raman reporters are those defined above.
- the present invention also relates to an optical fiber comprising a biosensor as detailed-above.
- the optical fiber may facilitate in vivo detection of the analyte and may be used for this purpose, for example in a method for the diagnosis of a disease by means of detecting the analyte in vivo.
- the optical fiber may be used for the detection of an analyte in vitro.
- the analyte may be a monosaccharide, in particular glucose, or an a-hydroxy acid.
- the above compounds of the invention are also contemplated for use as a monosaccharide, in particular glucose, or a-hydroxy acid receptor.
- the invention thus also covers methods for the detection of a monosaccharide, in particular glucose, or an ⁇ -hydroxy acid by using any of the compounds of the invention as a reporter.
- Step-1
- the yields of the addition reaction range between 80 - 90 %
- Step-1
- Step-2 A mixture of 3,3'-bipyridine (0.5 g, 3.2 mmol) and bromomethylphenylboronic acid (0.47 g, 3.8 mmol) in DMF (20 ml) was heated to 80 °C for two days. On the completion of the reaction, the mixture was cooled to 0 °C and mixed with acetone to precipitate the product. The precipitate was filtered off ahd washed with acetone (5 x 25 ml) to remove excess of DMF. The resultant solid was dried and lyophilized to afford the N,N'-Bis-(benzylboronic acid)-[3,3']bipyridinium Dibromide. Yield 1.2 g. (87 %). In general, the yields of the addition reaction range between 80 - 90 %
- Gold nanoparticles were prepared according to the reported protocols with the following changes. 25mg of hydrogen tetrachloroaurate (III) hydrate powder was added to 200ml of distilled water and the mixture was brought to rolling boil on a hot-plate with vigorous stirring. Afterwards, about 34.2 mg of sodium citrate dehydrate powder dissolved in 3ml of distilled water were rapidly added to the stirred tetrachloroaurate solution. The mixture was further boiled for 10 minutes, during which the solution exhibited several color changes starting with yellowish then purplish and finally ruby- red. The final solution was stored at 4°C until needed.
- hydrogen tetrachloroaurate (III) hydrate powder was added to 200ml of distilled water and the mixture was brought to rolling boil on a hot-plate with vigorous stirring. Afterwards, about 34.2 mg of sodium citrate dehydrate powder dissolved in 3ml of distilled water were rapidly added to the stirred tetrachloroaurate solution. The mixture was further boiled for 10 minutes,
- Example 4 Substrate fabrication using chemisorption of gold nanoparticles
- 3- Mercaptopropyltrimethoxy-silane solution 3MP-TMS
- Raman and SERS measurements were carried out in a Renishaw In Via Raman (UK) microscope system with an excitation laser at 633 nm.
- the laser intensity was set to 100% laser power.
- the Raman system was connected to a Leica microscope, wherein the laser light was coupled through a 50 X 0.75 N.A objective lens, which was used to excite the sample and also to collect the returning Raman signal.
- the detector to collect Raman signals was a Peltier cooled CCD.
- the WiRE 3.0 software package (provided with the Renishaw system) was used for instrument control and data acquisition. A 1800 1/mm grating was chosen for the spectral measurement with a resolution of about 1 cm -1 . Before each set of measurements the system was calibrated with a silicon standard (520cm _1 ).
- a bipyridinium compound (N,N'-Bis-(benzyl-3-boronic acid)-[4,4']bipyridinium Dibromide ( ⁇ ,4'-/w-BBV; BBV1)) was chosen as a reporting moiety for glucose sensing due to its intense SERS signal and ease of chemical functionalization by alkyl halides via quarternization of the nitrogen atoms to form viologens.
- Initial studies to evaluate the interaction of BBV1 with gold nanoparticles were carried out using UV visible spectroscopy and Transmission electron microscopy.
- Figure 3 shows the UV spectrum of gold nanoparticles in the presence and absence of BBV1.
- the BBV1 absorption peak was around 280 nra ( Figure 3) and did not interfere with the gold absorption at 520 nm.
- an additional peak appeared around 800 nm.
- the intensity at the 520 nm peak decreased and the additional peak underwent a red shift, indicating that BBV1 caused the aggregation of the gold nanoparticles.
- a 2D substrate array was prepared, consisting of approximately 40 nm gold nanoparticles on a modified glass support.
- the glass surface was modified by thiol groups ( Figure 4) and chemisorption of the nanoparticles carried out using citrate stabilized gold nanoparticles (C-Au) synthesized by the Turkevich method (Kimling et al. J. Phys. Chem. B 2006, 110, 15700-15707).
- C-Au citrate stabilized gold nanoparticles synthesized by the Turkevich method.
- the SERS intensity from these substrates was recorded for 10 seconds using 633 nm at a maximum laser power of 6.2 mW.
- a large number of glucose sensing experiments were carried out and the spectral data from a typical experiment under physiological conditions are shown in Figure 5.
- the BBVl SERS spectrum shows an increase in intensity that is proportional to the increase in glucose concentration. All the peaks of the BBVl SERS spectrum show a varying degree of sensitivity to glucose concentrations. The most representative peaks at six different wave numbers were followed for glucose response and demonstrated the possibility to apply the detection in a multiplexing or ratiometric approach.
- the glucose sensing profiles for the four major peaks are shown in Figure 6.
- Example 8 Optimization for low glucose levels
- the glucose sensing data from Figure 6 indicates that the used configuration the SERS system was more sensitive to the higher end of the physiologically relevant concentration, i.e. 10-25 mM.
- the amount of BBVl adsorbed to the nanoparticle surface was increased.
- the measurements were carried out again and the obtained data showed that the sensitivity of the assay was shifted to the lower end of the tested glucose concentrations.
- Figure 7 depicts the glucose sensing experiment, wherein the 1620 cm "1 peak intensity in the SERS spectrum was followed at different BBVl concentrations (left graph: 1 ⁇ BBVl 12 h; right graph: 1 mM BBVl).
- the obtained results clearly demonstrate the advantages of this two component (receptor molecule-nanoparticle) approach that allows tuning the sensitivity of the SERS assay to the desired range.
- bipyridine salts that lack the boronic acid moiety (4,4'-BV; 3,4'-BV and 3,3 '-BV; Figure 8) were synthesized and subjected to glucose sensing conditions. As expected, there was no glucose response when any of these compounds was used for the SERS-based glucose detection. The SERS spectrum was not significantly changed upon a systematic change in glucose concentration.
- Example 10 BBV compounds for the detection of glucose
- the SERS intensity from this substrate was recorded for 10 seconds using 633 nm at a maximum laser power of 0.62 mW.
- Figure 11 shows the glucose response of 3,4'-o-BBV SERS spectrum peak at 1620 cm-1.
- Example 12 Hydrophobic SERS glucose sensors
- the experiments were focused on high cross section aromatic boronic acids which can bind with gold nanoparticles via hydrophobic interactions.
- the molecules bound to the nanoparticle surface can be further stabilized by thiolated PEG/small molecule encapsulation to allow their use in biosensing.
- a boronate ester is formed which leads to a change in the SERS spectrum of the nanoparticle-reporter complex that can be monitored spectroscopically.
- Two representative examples of these molecules that allow the SERS-based glucose detection are shown in Figure 12. Compounds of this class are insoluble in aqueous media. However, suitable experimental conditions allowing their immobilization on citrate stabilized gold nanoparticles were identified.
- 4-(6-Mercaptopurin-9-ylearbonyl)phenyl boronic acid and 3-(6-Mercaptopurin-9- ylcarbonyl)phenyl boronic acid were covalently anchored via their mercapto groups on the surface on the produced SERS substrate by incubating the substrate with 1 ⁇ of a solution of 4-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid or 3-(6- Mercaptopurin-9-ylcarbonyl)phenyl boronic acid in ethanol overnight. Thereafter the substrate was washed with ethanol several times to remove the non-covalently bound molecules and used in glucose sensing in a flow cell configuration as in the experiment of 3,4'-o-BBV.
- FIG. 17 An exemplary design of a fiber optic probe according to the invention is schematically shown in Figure 17. Such a device may be used in in vitro diagnostics or in a minimal invasive in vivo setup.
- SERS substrates Six pieces of SERS substrates were incubated with ImM BBV1 solution overnight. Afterwards, the substrates were removed from the BBV1 solution and rinsed one time with 10 mL of deionized water. The substrates were then removed from the glucose solution and placed on glass a glass microscopic slide with a cover glass. The SERS spectra of all the substrates were recorded using a 633 nm laser, as described above, with 10 second acquisition time. For each substrate the SERS spectrum was recorded at 8 different points, collecting three different accumulations at each point.
- Each of the BBV1 treated and SERS analyzed substrates was then immersed in 2ml glucose solutions of the following concentrations 0, 5mM, lOmM, 15mM, 20mM and 25mM in PBS for 30 minutes.
- the substrates were then removed from the glucose solution and placed on a glass microscopic slide with a cover glass.
- the SERS spectra from these substrates were recorded at eight different points, wherein for each point an average of three spectra was calculated.
- Step b
- 5-pyridin-3-ylpyridine-3-carboxylate is dissolved in THF. To the solution concentrated HC1 is added and the solution boiled under reflux.
- Step b thionyl chloride is added and the solution further boiled under reflux.
- step e For the formation of the thioester derivative, the compound of step c is mixed with the corresponding bis-thiol and under addition of Et3N in methylenchoride as solvent the reaction is stirred for 12 hrs. Step e:
- N,N'-Bis-(benzylboronic acid)-[4,4'] bipyridinium (poly)ethylene glycol thioalkyl thioester Dibromide is obtained by mixing the compound of step d and bromomethylphenylboronic acid in DMF (20 ml). The mixture was heated at 80 °C for two days. On completion of the reaction, it was cooled down to 0 °C and added to acetone resulting in the formation of a precipitate. The precipitate was filtered off and washed with further acetone (5 x 25 ml) to remove excess DMF.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The present invention relates to a method for detecting an analyte, such as glucose, using Surface Enhanced Raman Spectroscopy (SERS), including contacting the analyte with one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives attached to a metal surface that enhances Raman scattering, in particular a nanoparticle surface; and detecting a surface enhanced Raman signal from said compound. The invention further relates to new receptor compounds useful in such a method as well as biosensors including these compounds, optical fibers including such biosensors and methods of using these receptor compounds, biosensors and optical fibers for analyte detection.
Description
METHOD FOR THE DETECTION OF AN ANALYTE BY SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS)
Field of the invention
The present invention relates to a method, device and compounds for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS).
Background
Development of a reliable and inexpensive continuous glucose monitoring system has been a long-standing aim of biomedical device research for the management of diabetes mellitus. Several methods have been explored with very limited success, even after years of extensive research and so far only few sensors have reached an advanced stage of development. An optical sensor for a walking diabetic could be more researched since technology already exists for making them minimally invasive through miniaturization of components. Such a device can also be used in critical care medicine for tight glycemic control, which has proven to have a dramatic improvement in recovery rate and 34% reduction in overall mortality. The current sensors are based on glucose oxidase; their performance is limited by factors, such as oxygen dependence, poor accuracy in the hypoglycemic range and consumption of glucose while making a measurement. A solution to these problems could be a sensor based on reversible binding of glucose to an artificial receptor, such as boronic acid. Ability of boronic acids to bind to glucose reversibly under physiological conditions is well documented in literature. A sensing system based on this interaction offers considerable advantages in terms of stability and ease of fabrication. A method of glucose sensing with a boronic acid functionalized dye is for example disclosed in US 5,137,883. In 1992 Yoon and Czarnik reported the first scientific study on boronic acid based glucose sensing using anthracenyl boronic acid which produced a measurable change in fluorescent intensity upon binding to glucose in solution (Yoon & Czarnik, J. Am. Chem. Soc. 1992;114:5874-5875). Since this seminal report, Shinkai and others (Kawanishi et al., J Fluorescence 2004; 14:5,499-512; Arimori et al., Tetrahedron Letters 2001, 42(27),
4553-4555; Norrild & Sotofte, Journal of the Chemical Society, Perkin Transactions 2 2002, (2), 303-311; Ma & Yang, Journal of Electroanalytical Chemistry 2005, 550(2), 348-352; Wang et al., Journal of Organic Chemistry 2005, 70(14), 5729-5732; Kanekiyo & Tao, Chemistry Letters (2005), 34(2), 196-197) have developed several abiotic sensing systems using boronic acids. All of these studies, which are based on fluorophores to which a boronic acid is appended, helped to establish the scope of this technique. Different boronic acid based glucose sensors are known in the art (International patent publication WO 2004/096817; U.S. Pat. Appl. No. 2005191761 ; U.S. Pat. Appl. No. 2005124020; Cappuccio et al., Journal of Fluorescence (2004), 14(5), 521-533). Yet, there is still need in the art for a sensor that can function efficiently under physiological conditions. The main challenges to achieve glucose sensing under physiological conditions include feasibility of transferring sensing components in minimally invasive platform such as optical fibers or implantable substrates.
Vibrational spectroscopic techniques namely infra red (IR), normal Raman and Surface Enhanced Raman (SER) have been considered for glucose detection. Since near IR and mid IR technique suffers with the limitation of competing absorption from aqueous media, Raman spectroscopic techniques have evolved as the methods of choice. Raman spectroscopy has been used as valuable tool for structural information due to the molecular vibrational finger prints available by the spectrum. However, the applications were limited under biological conditions mainly due to the poor sensitivity and the need for high laser power and complicated instrumentation. Most of these drawbacks were overcome by the development of Surface Enhanced Raman spectroscopy (SERS) where the spectral intensity is enhanced tremendously by the interaction of the analyte molecules with a nanoparticle surface of gold or silver. There are many cases where these enhancement factors are up to the level of single molecule detection (Nicholas & Ricardo, Chem. Soc. Rev., 2008, 37, 946-954). However, the detection of molecules with such extraordinary enhancement depends on the properties of the molecule-nanoparticle ensemble and is limited to certain classes of aromatic molecules. However, due to the very poor Raman cross section of glucose leading to a relatively weak SERS spectrum, the SERS based detection of glucose is still considered
a challenge. Since the glucose sensing by SERS depends on the interaction of glucose with the surface of the Raman active surface, a lot of effort has been placed towards meeting with the challenge of designing methodology to bring glucose molecules close enough to the nanoparticle surface with reliable SERS response. One approach tested is to treat the silver film over the nanosphere surface with a mixture of aliphatic thiols which effectively partition glucose near the SERS active surface even in presence of biological fluids in a reproducible manner (Yonzon et al., Anal. Chem. 2004, 76, 78-85). This technique is being implemented in an implantable sensor and tested in vivo and successful sensing studies in an animal model have been reported (Stuart et al., Anal. Chem., 2006, 78, 721 1-7215; U.S. patent application No. 200901 18605; U.S. patent application Ser. No. 10/652,280; U.S. Provisional Patent Application Ser. No. 60/407,061). Other techniques included capturing glucose using well known synthetic sugar receptors (Kanayama & Kitano, Langmuir, 2000, 16 (2), 577-583). However, when these receptors were covalently anchored to the surface to follow the vibrational peaks of glucose, sensitivity of the resulting SERS sensor was not good enough for practical applications. Hence, there is still need for methods that overcome the above- detailed limitations.
Summary of the Invention
The present invention provides for methods, devices and compounds for the sensitive analyte detection using SERS.
In a first aspect, the present invention thus relates to a method for detecting an analyte using surface enhanced Raman spectroscopy (SERS), including contacting the analyte with one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives, wherein the one or more compounds are attached to a metal substrate surface that enhances Raman scattering; and detecting a surface enhanced Raman signal from said compound.
In various embodiments of this method, the surface enhanced Raman signal of the compound is correlated with the amount of the analyte.
In further embodiments, this method is suitable for the detection of the analyte in vivo or, alternatively, the analyte may be contained in a sample and the detection is in vitro.
Other embodiments of the method allow that the analyte is detected in a bodily fluid comprising said analyte. Preferably, this bodily fluid is selected from the group consisting of plasma, serum, blood, lymph, liquor and urine.
In a particular embodiment, the analyte to be detected is an a-hydroxy acid or a monosaccharide, such as glucose.
In certain embodiments of the above-detailed method, the compound is attached to the substrate surface via electrostatic, hydrophobic or covalent interactions.
In various embodiments, the compound is selected from the group consisting of phenyl boronic acid derivatives, pyridyl boronic acid derivatives and bipyridyl boronic acid derivatives and salts thereof. The compound may for example be a boronic acid substituted benzyl viologen or a 3- or 4-(purin-9-ylcarbonyl)phenyl boronic acid or salt thereof.
In further embodiments of the claimed method the compounds are covalently attached to the substrate surface via a linker. In one embodiment, the linker comprises at least one thiol group that facilitates binding to the substrate surface. In various embodiments, the linker may comprise an ethylene glycol of the formula -(0-CH2-CH2)„- , wherein n is an integer from 1 to 10.
In other embodiments of the invented method, the compound is either positively charged and attached to the substrate surface by electrostatic interactions or the compound is hydrophobic and attached to the substrate surface by hydrophobic interactions.
In various embodiments of the claimed method, the compound can be selected from the group consisting of:
N,N'-Bis-(benzyl-3-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[J,4']bipyridinium Dibromide (J,4'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,4']bipyridinium Dibromide (J,4'-/?-BBV);
N,N'-Bis-(benzyl-3-boronic acid)-[3,3']bipyridinium Dibromide (3,3 -m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[3,3']bipyridinium Dibromide (J,3'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,3']bipyridinium Dibromide (3,3'- ?-BBV);
N,N'-Bis-(benzyl-3-boronic acid)-[4,4']bipyridinium Dibromide (¥,4'-m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[¥,4']bipyridinium Dibromide (4,4'- -BBV);
3- (6-Mercaptopurin-9-ylcarbonyl)phenylboronic acid;
4- (6-Mercaptopurin-9-ylcarbonyl)phenylboronic acid;
2-((3-Mercaptoethylcarbonyl)amino)-5-pyridyl boronic acid;
Pyrene-l-boronic acid; and
Benzothiophene-2-boronic acid;
or salts thereof. In some embodiments, the substrate used in the claimed method is a nanoparticle. The nanoparticle may be coated with, comprise or consist of a noble metal. In one embodiment, the noble metal is selected from gold and silver. In specific embodiments, the nanoparticle is a nanoparticle coated with a silver film or a citrate-stabilized gold nanoparticle.
In another aspect, the present invention relates to a biosensor for the detection of an analyte using surface-enhanced Raman spectroscopy, comprising a plurality of nanoparticles, wherein one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives are attached to the nanoparticle surface.
In one embodiment, the biosensor further comprises a substrate, wherein said nanoparticles are adherent to the substrate. Preferably, the biosensor is configured for in vivo and/or in vitro use. In one embodiment of the above biosensor, the analyte detected by the biosensor is an a-hydroxy acid or a monosaccharide, such as glucose. The biosensor may be configured for quantitative detection of glucose in a physiological concentration range.
In various embodiments, the one or more compounds of the above biosensor are attached to the substrate surface via electrostatic, hydrophobic or covalent interactions.
The one or more compounds may be selected from the group consisting of phenyl boronic acid derivatives, pyridyl boronic acid derivatives and bipyridyl boronic acid derivatives or salts thereof, such as boronic acid substituted benzyl viologens or salts thereof.
In some embodiments, the one or more compounds are covalently attached to the substrate surface via an organic linker, such as a linker which comprises at least one thiol group that facilitates binding to the substrate surface. In one embodiment, the linker comprises an ethylene glycol of the formula -(0-CH2-CH2)n-, wherein n is an integer from 1 to 10.
In other embodiments, the one or more compounds of the biosensor are either positively charged and attached to the substrate surface by electrostatic interactions or hydrophobic and attached to the substrate surface by hydrophobic interactions.
In certain embodiments of the biosensor, the nanoparticle is coated with, comprising or consisting of a noble metal. This noble metal is preferably selected from gold and silver. In a certain embodiment thereof, the nanoparticle is coated with a silver film. In another embodiment of the biosensor, the nanoparticle is a citrate-stabilized gold nanoparticle.
Formula I
wherein
A is heteroaryl and comprises at least one nitrogen atom,
L is a linker selected from the group consisting of -C(O)-, -C(0)-0-, -(CH2)m-, - C(=CH2)-, -C(0)-NH-, -NH-C(O)-, -0-, -S-, =CH- and -CH=, wherein m is an integer from 1 to 3;
L2 is a linker selected from the group consisting of a direct bond between A and SH, - C(0)-0-(CH2)q-, -C(0)-S-(CH2)q-, -(CH2)p-, -C(0)-S-(0-CH2-CH2)n-, -C(0)-S -(CH2- CH2-0)n-, -C(0)-S -<CH2-CH2-0)„-(CH2)q- and -C(0)-S -(0-CH2-CH2)n-(CH2)q-, wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and q is an integer from 1 to 5;
B is aryl; and salts thereof. These compounds may have use as Raman receptors for monosaccharides or alpha- hydroxy acids.
In various embodiments, A is selected from the group consisting of purinyl, indolyl, pyridinyl, bipyridyl, pyrimidinyl, azaindolyl, pyrrolyl, pyrazinyl, pyridazinyl, isoindolyl, benzimidazolyl, imidazolyl and indazolyl. B is preferably selected from phenyl or naphthyl.
In some embodiments of the above compounds, L is bound to A via the at least one nitrogen atom of the heteroaryl ring.
In various embodiments, L is -C(O)-. In further embodiments, L is -C(O)-, A is purinyl, L2 is a direct bond and B is phenyl.
In one embodiment, the compounds are of Formula II:
Formula II.
In other embodiments of the claimed compounds, L is -(CH2)m-. In some embodiments, L is -(CH2)m-, A is purinyl, L2 is a direct bond and B is phenyl.
In one embodiment, the compound is of Formula III:
Formula III.
In a still further embodiment of the compounds falling within general Formula I, A is bipyridyl, L is -(CH2)m-, L2 is -(CH2)P-, and B is phenyl. In one specific embodiment thereof, A is 4,4 '-bipyridyl, and L and L2 are bound to A via the nitrogen atoms of the bipyridyl moiety. embodiment, the compound is of Formula IV:
Formula IV
wherein X" is chloride, bromide, iodide or fluoride. In various embodiments of the above compounds of Formulae I-IV, the boronic acid substituent is in the m- or p-position of the aromatic (phenyl) ring. In further various embodiments, A is purinyl and the thiol substituent is in the 2- or 6-position of the purine ring. The compounds of the invention may be halogen salts, such as the respective bromide salts.
In various embodiments, the compounds are compounds of Formula V
Formula V
wherein X" is chloride, bromide, iodide or fluoride, and D is selected from the group consisting of-(CH2)p-, -(0-CH2-CH2)n-, -(CH2-CH2-0)n-, -(CH2-CH2-0)n-(CH2)m- and -(0-CH2-CH2)n-(CH2)m-) wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and m is an integer from 1 to 5.
In one embodiment thereof, the compound is a compound of Formula VI
Formula VI
wherein X" is chloride, bromide, iodide or fluoride, and n is an integer from 1 to 10.
In further embodiments of the compounds of Formulae V or VI, the pyridyl rings are connected such as to form a 3,4'-, 4,3?-, 3,3'- or 4,4'-bipyridyl structure. In certain embodiments, the bipyridyl benzyl boronic acid moiety is selected from the group consisting of:
N,N'-Bis-(benzyl-3 -boronic acid)-[3,4']bipyridinium Dibromide (J,4'-m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-p-BBV);
N,N'-Bis-(benzyl-3-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,3']bipyridinium Dibromide (3,3'- -BBV);
N,N'-Bis-(benzyl-3 -boronic acid)-[4,4']bipyridinium Dibromide (4,4'-w-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[4,4']bipyridinium Dibromide (^,4'-o-BBV); and
N,N'-Bis-(benzyl-4-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-p-BBV).
Further embodiments of the above compounds are the compounds, wherein the -C(O)- S-(CH2-CH2-0)n-CH2-SH or the -C(0)-S-D-SH group is in the m-position relative to the nitrogen atom of the pyridine ring.
In one aspect of the invention, in the method according to the invention detailed above any one or more of the above-mentioned compounds are used.
In a still further aspect, the invention relates to the biosensor according to the invention, wherein the biosensor comprises one or more of the above compounds of the invention.
The present invention also relates to an optical fiber comprising a biosensor according to the invention. In another aspect, the present invention features the use of any one of the above- mentioned compounds as a monosaccharide, in particular glucose, or a-hydroxy acid receptor.
In a further aspect, the present invention relates to the use of the biosensor or the optical fiber according to the invention for the detection of an analyte. In one embodiment, the detection is in vivo. In another embodiment the detection is in vitro. In various embodiments, the analyte is a monosaccharide, such as glucose, or an a-hydroxy acid.
Brief Description of the Drawings
Figure 1 shows a schematic representation of the major components of the SERS based analyte sensing system using reporter molecules. The exemplary analyte referred to in the figure is glucose, but the claimed invention is not limited thereto. The reporter molecule can attach to the nanoparticle by electrostatic, covalent or hydrophobic interactions and upon glucose binding change the intensity or position of SERS signals. These changes can be monitored as glucose sensing event at the molecular level.
Figure 2 shows the proposed mechanism of analyte/glucose detection by SERS using a benzyl viologen as a reporter molecule and a gold nanoparticle as the SERS active surface.
Figure 3 shows UV studies of benzyl viologen boronic acids with 40 run gold nanoparticles. BBV1 has a Xmax at 259.5 nm and an Au nanoparticle has a max at 527
nm. When BBV1 and the Au nanoparticles are present together, the aggregation leads to the shift of the plasmon peak to 752 nm.
Figure 4 schematically shows the manufacturing protocol for a glucose sensing substrate (a). Figure 4 (b) shows the Emission Scanning Electron Microscopy (ESEM) characterization of the morphology of the glucose sensing substrate, and Figure 4 (c) shows SERS spectrum of BVB1 on the glucose sensing substrate. Figure 4 d) shows a Raman spectrum of BBV1 in powder form for comparison.
Figure 5 shows the response of the SERS spectrum of BBV1 upon glucose binding under physiologically relevant conditions. The actual base line is shifted from zero for clarity reasons.
Figure 6 shows the response of the four major SERS peaks of BBV1 on novel glucose sensing substrates upon glucose binding under physiological conditions.
Figure 7 shows the glucose responsiveness of the SERS peak of BBV1 under physiological conditions under different BBV1 concentrations: a) Glucose response from SERS substrate incubated with 1 μΜ BBV1 (left graph), b) Glucose response from the SERS substrate incubated with 1 mM BBV1 (right graph).
Figure 8 shows the chemical structures of benzyl viologen control compounds. The lack of glucose receptive boronic acid moieties makes them unresponsive to glucose. Figure 9 shows the chemical structures of all possible isomers of BBV1 that are synthesized and characterized with 4,4'-; 3,3'- and 4,3'- bipyridine moieties as the SERS reporting core.
Figure 10 shows the SERS spectrum of the all possible isomers of BBV1 that were synthesized to evaluate the glucose sensibility and glucose selectivity of this class of Raman reporter molecules.
Figure 11 shows the glucose response of 3,4'-o-BBV SERS spectrum peak at 1620 cm- 1.
Figure 12 shows representative examples of boronic acid derivatives that can be immobilized by hydrophobic interaction on gold nanoparticles for glucose sensing using SERS mode in solution.
Figure 13 shows the SERS spectrum of a) thionaphthene boronic acid and b) pyrene boronic acid in milliQ water after mixing with 40 nm citrate stabilized gold nanoparticles.
Figure 14 shows glucose response from thionaphthene boronic acid immobilized gold nanoparticles.
Figure 15 shows the SERS spectrum of 4-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid (A) and 3-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid (B) covalently anchored via their mercapto groups on the surface on the produced SERS substrate.
Figure 16 shows the glucose response of 4-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid by determining the SERS intensity of the peak at 1001 cm"1 in a flow cell experiment where glucose concentration was systematically varied.
Figure 17 schematically shows an exemplary design of an optical fiber coupled to a biosensor according to the present invention.
Detailed Description The following detailed description refers, by way of illustration, to specific details and embodiments in which the invention may be practiced.
This invention relates to a novel method, device and compounds for detecting an analyte, specifically an analyte with poor Raman cross section, using Surface Enhanced Raman Spectroscopy (SERS).
In a first aspect, the present invention relates to a method for detecting an analyte using surface enhanced Raman spectroscopy (SERS), comprising contacting the analyte with one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives, wherein the one or more compounds are attached to a metal substrate surface that enhances Raman scattering; and detecting a surface enhanced Raman signal from said compound.
The compounds used in this method are Raman reporters, i.e. compounds which have a high Raman cross section and the Raman vibrational "finger print" is detectably altered, for example by a shift and/or an increase in intensity, upon the binding an analyte, such
as to allow detection and quantitation of the analyte. Accordingly, the compounds can also be considered to represent reporters or receptors of the analyte, for example glucose reporters or receptors. The compounds can be stably adsorbed at a surface that enhances the Raman signal from the compound, such as a nanoparticle or other SERS active substrate surface by reversible electrostatic interaction, hydrophobic interaction or covalent anchoring. Ideally, the compound has a high Raman cross section and the capability to adsorb strongly on the surface of a metal nanoparticle in aqueous media so that it gives a fast and intense and non fluctuating SERS signal that is proportional to the concentration of the analyte, such as glucose, in bulk.
Generally, SERS using Raman reporters is advantageous over the prior art glucose oxidase based systems as it is independent of oxygen. In addition, the methods according to the invention allow the detection of analytes in lower concentration ranges, such as glucose in hypoglycemic concentration range, and thus provide a more reliable readout in the analysis of patients. By varying the amount of immobilized compound at the substrate surface, the detection range can be suitably adjusted to the desired analyte concentration range thus ensuring a linear measurement range. Compared to the methods of the prior art, a further advantage of the receptors of the present invention is that they selectively, reversibly and covalently bind to the analyte; stably enough to allow a strong SERS mediated analyte detection and reversible in order to avoid a permanent loss of analyte binding sites and analyte. As the Raman reporter selectively binds to the analyte, a more specific readout is accomplished. In addition, due to the fact that the Raman reporters are adsorbed at biocompatible substrates, such as noble metals, they can detect the desired analyte under physiological conditions, meaning that the sensing components can be integrated in a minimally invasive platform, such as optical fibers or implantable substrates. This is a clear advantage over previous approaches, e.g. those using Quantum dots, which, due to their inherent toxicity, are not suitable for implantation. In addition, the substrates of the present invention bind the Raman reporters but bind other molecules to a very low extent and thus provide a longer lasting setup, in particular in an implanted biosensor setup. As the methods of the invention do
not rely on fluorescence, they overcome previous limitations of methods based on fluorescent dyes or Quantum dots, as they are not hampered by photo bleaching, broad emission profiles and peak overlapping. Moreover, the SERS-based detection methods of the invention are suitable for multiplexing, which is another advantage, both in context of sensing experiments to understand complex mechanistic pathways in biological studies and in personalized medicine.
The inventors of the present invention have surprisingly found that derivatives of aryl boronic acids, heteroaryl boronic acids, aryl boronates and heteroaryl boronates are particularly useful as Raman reporters and receptors in the SERS detection methods of the invention. Usually, in absence of analyte, these receptors exist in their trigonal neutral form. The formation of the more-acidic boronate-analyte complex shifts the acid-base equilibrium of the boronic acid towards its anionic tetrahedral "-ate" form, causing electronic and/or steric changes. This change in molecular structure causes a significant change in the orientation and distance of the molecule from the nanoparticle surface leading to a change in the SERS intensity of the molecular core.
The compounds according to the invention are aryl or heteroaryl boronic acid derivatives or aryl or heteroaryl boronate derivatives. In this connection, "aryl boronic acid" or "aryl boronate" relates to organoboranes with a carbon boron bond, wherein a boric acid or salt or ester thereof is substituted with an aryl moiety. These compounds have the general structure R-B(OH)2, wherein R is the aryl moiety. In the salts or esters of such compounds the hydrogen atoms may be replaced by organic residues or suitable cations. The aryl moieties of the present invention preferably comprise 5-20 carbon atoms and can comprise 1-5 rings, which are either condensed or connected by bonds. Examples of aryl moieties according to the invention include, but are not limited to phenyl, naphthyl, pyrenyl and anthracenyl. Preferred are phenyl moieties, thus forming phenyl boronic acids. Similarly, "heteroaryl boronic acid" and "heteroaryl boronate" relates to organoboranes with a carbon boron bond, wherein a boric acid or salt or ester thereof is substituted with a heteroaryl moiety. These compounds also have the general structure R-B(OH)2, wherein R is the heteroaryl moiety. In the salts or esters of such compounds the hydrogen atoms may be replaced by organic residues or suitable cations.
The heteroaryl moieties of the present invention preferably comprise 5-20 carbon atoms and can comprise 1-5 rings, which are either condensed or connected by bonds, wherein at least one of the ring carbon atoms is replaced by nitrogen, oxygen or sulfur. Examples of heteroaryl moieties according to the invention include, but are not limited to purinyl, indolyl, pyridinyl, bipyridyl, pyrimidinyl, azaindolyl, pyrrolyl, pyrazinyl, pyridazinyl, isoindolyl, benzimidazolyl, imidazolyl, indazolyl, chinolinyl, isochinolinyl, acridinyl and benzothiophenyl.
The term "derivatives" in relation to the compounds of the present invention means that the aryl/heteroaryl boronic acid/boronate structure can be substituted with further substituents or groups and can thus be part of a larger molecule. When the aryl or heteroaryl group is further substituted, the substituents are one or more, preferably 1-5 groups, selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalicyclic, alkoxy, cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, hydroxy, halo, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NR'R2 where R1 and R2 are independently selected from the group consisting of hydrogen, C1-C4 alkyl, C3-C8 cycloalkyl, C6-C14 aryl, carbonyl, acetyl, sulfonyl, amino, and trifluoromethanesulfonyl, or R1 and R2, together with the nitrogen atom to which they are attached, combine to form a five-or six-membered heteroalicyclic ring. In addition, two or more of the aryl/heteroaryl boronic acid/boronate derivatives may be coupled to each other thus forming a bis(benzyl boronic acid) viologen.
"Alkyl" refers to a saturated aliphatic hydrocarbon including straight chain, or branched chain groups. Preferably, the alkyl group has 1 to 10 carbon atoms (whenever a numerical range; e.g.,"l-10", is stated herein, it means that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 10 carbon atoms). More specifically, it may be a medium size alkyl having 1 to 6 carbon atoms or a lower alkyl having 1 to 4 carbon atoms e. g., methyl, ethyl, n- propyl, isopropyl, butyl, iso-butyl, tert-butyl and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent group(s) is one or more, for example one or two groups, individually selected from the group consisting of C3-C¾
cycloalkyl, C6-C14 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicychc wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, C Cjo alkoxy, C3-C8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NRJR2 where R and R are independently selected from the group consisting of hydrogen, Ci- C4 alkyl, C3-Cg cycloalkyl, C6-CH aryl, carbonyl, acetyl, sulfonyl, amino, and trifluoromethanesulfonyl, or R10 and R11, together with the nitrogen atom to which they are attached, combine to form a five-or six-membered heteroalicychc ring.
A "cycloalkyl" group refers to an all-carbon monocyclic ring (i.e., rings which share an adjacent pair of carbon atoms) of 3 to 8 ring atoms wherein one of more of the rings does not have a completely conjugated pi-electron system e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like. Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, adamantane, cyclohexadiene, cycloheptane and, cycloheptatriene. A cycloalkyl group may be substituted or unsubstituted. When substituted, the substituent group(s) is one or more, for example one or two groups, individually selected from Ci-Cio alkyl, C3-C8 cycloalkyl, C6-C14 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicychc wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Ci-Cio alkoxy, C3-C8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NR'R2, with R1 and R2 as defined above.
An "alkenyl" group refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon double bond e. g., ethenyl, propenyl, butenyl or pentenyl and their structural isomeric forms such as 1-or 2-propenyl, 1-, 2-, or 3-butenyl and the like.
An "alkynyl" group refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon triple bond e. g., acetylene, ethynyl, propynyl, butynyl, or pentynyl and their structural isomeric forms as described above. An "aryl" group, as used herein in connection with the substituent groups, refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups of 6 to 14 ring atoms and having a completely conjugated pi- electron system. Examples, without limitation, of aryl groups are phenyl, naphthenyl and anthracenyl. The aryl group may be substituted or unsubstituted. When substituted, the substituted group(s) is one or more, for example one, two, or three substituents, independently selected from the group consisting of Q-Cio alkyl, C3-C8 cycloalkyl, C6- Ci4 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicyclic wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Q-Cio alkoxy, C3-Cg cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, trihalomethyl, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino, and -NR'R2, with R1 and R2 as defined above.
A "heteroaryl" group, as used herein in connection with the substituent groups, refers to a monocyclic or fused aromatic ring (i.e., rings which share an adjacent pair of atoms) of 5 to 10 ring atoms in which one, two, three or four ring atoms are selected from the group consisting of nitrogen, oxygen and sulfur and the rest being carbon. Examples, without limitation, of heteroaryl groups are pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,3,4- triazinyl, 1 ,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnnolinyl, napthyridinyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5, 6, 7, 8- tetra-hydroisoquinolyl, purinyl, pteridinyl, pyridinyl, pyrimidinyl, carbazolyl, xanthenyl or benzoquinolyl. The heteroaryl group may be substituted or unsubstituted. When substituted, the substituted group(s) is one or more, for example one or two substituents,
independently selected from the group consisting of Ci-C)0 alkyl, C3-C8 cycloalkyl, C6- C14 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicyclic wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Ci-C]0 alkoxy, C3-C8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, trihalomethyl, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitro, silyl, sulfinyl, sulfonyl, amino,
1 2 1 2
and -NR R , with R and R as defined above. In one embodiment, if heteroaryl is pyridyl, the substituent is pyridyl to give bipyridyl. A "heteroalicyclic" group refers to a monocyclic or fused ring of 5 to 10 ring atoms containing one, two, or three heteroatoms in the ring which are selected from the group consisting of nitrogen, oxygen and -S(0)„ where n is 0-2, the remaining ring atoms being carbon. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system. Examples, without limitation, of heteroalicyclic groups are pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, tetrahydropyridazine, tetrahydrofuran, thiomorpholine, tetrahydropyridine, and the like. The heteroalicyclic ring may be substituted or unsubstituted. When substituted, the substituted group (s) is one or more, for example one, two, or three substituents, independently selected from the group consisting of Q- Cio alkyl, C3-C8 cycloalkyl, C6-Ci4 aryl, 5-10 membered heteroaryl wherein 1 to 4 ring atoms are independently selected from nitrogen, oxygen or sulfur, 5-10 membered heteroalicyclic wherein 1 to 3 ring atoms are independently nitrogen, oxygen or sulfur, hydroxy, Q-Cio alkoxy, C3-C8 cycloalkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, trihalomethyl, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, nitrb, silyl, sulfinyl, sulfonyl, amino, and -NR'R2, with R1 and R2 as defined above.
A "hydroxy" group refers to an -OH group.
An "alkoxy" group refers to an -O-unsubstituted alkyl and -O-substituted alkyl group, as defined herein. Examples include and are not limited to methoxy, ethoxy, propoxy, butoxy, and the like.
A "cycloalkoxy" group refers to a -O-cycloalkyl group, as defined herein. One example is cyclopropyloxy.
An "aryloxy" group refers to both an -O-aryl and an -O-heteroaryl group, as defined herein. Examples include and are not limited to phenoxy, naphthyloxy, pyridyloxy, furanyloxy, and the like.
A "mercapto" group refers to a -SH group. An "alkylthio" group refers to both an S-alkyl and an -S-cycloalkyl group, as defined herein. Examples include and are not limited to methylthio, ethylthio, and the like.
An "arylthio" group refers to both an -S-aryl and an -S-heteroaryl group, as defined herein. Examples include and are not limited to phenylthio, naphthylthio, pyridylthio, furanylthio, and the like.
A "sulfinyl" group refers to a -S(0)-R' group, wherein, R' is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, ar; yl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), as defined herein.
A "sulfonyl" group refers to a -S(0)2R' group wherein, R' is selected from the group consisting of hydrogen, hydroxy, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), as defined herein. A "trihalomethyi" group refers to a -CX3 group wherein X is a halo group as defined herein e. g., trifluoromethyl, trichloromethyl, tribromomethyl, dichlorofluoromethyl, and the like.
"Carbonyl" refers to a -C(=0)-R' group, where R' is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), as defined herein. Representative
examples include and the not limited to acetyl, propionyl, benzoyl, formyl, cyclopropylcarbonyl, pyridinylcarbonyl, pyrrolidin-l-ylcarbonyl, and the like.
A "thiocarbonyl" group refers to a -C(=S)-R' group, with R' as defined herein.
"C-carboxy" and "carboxy" which are used interchangeably herein refer to a -C(=0)0- R" group, with R" as defined herein, e. g. -COOH, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, and the like. An "O-carboxy" group refers to a -OC(=0)R' group, with R' as defined herein, e.g. methylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, and the like.
An "acetyl" group refers to a -C(=0)CH3 group. A "carboxylic acid" group refers to a C-carboxy group in which R' is hydrogen.
A "halo" or "halogen" group refers to fluorine, chlorine, bromine or iodine.
A "cyano" group refers to a -CN group.
A "nitro" group refers to a -N02 group.
An "amino" group refers to an -NR'R2 group, wherein R1 and R2 are independently hydrogen or unsubstituted lower alkyl, e.g., -NH2, dimethylamino, diethylamino, ethylamino, methylamino, and the like.
The term "detection", as used herein, refers to the identification of the presence or absence of an analyte and/or quantifying its amount. The analyte can be detected in a concentration range of mM, below mM, below μΜ, below nM, below pM, below fM or at a single molecule level.
Surface Enhanced Raman Spectroscopy, or Surface Enhanced Raman Scattering, abbreviated SERS, is a surface sensitive technique that results in the enhancement of Raman scattering by molecules adsorbed on metal surfaces. The enhancement factor can be as much as 10I4-1015, which allows the technique to be sensitive enough to detect single molecules.
Substrates suitable in the present invention comprise nanoparticles, in particular nanoparticles made of materials or coated with materials which enhance the Raman signal of a substrate-attached compound. Examples for such materials that are capable of enhancing the Raman signal of a compound attached thereto are noble metals, such as copper, silver or gold. If nanoparticles are used as a substrate, the nanoparticles may be made of plastic, ceramics, composites, glass or organic polymers and coated with the metal of choice, such as silver or gold. Alternatively, the nanoparticles may be made of a metal, for example a noble metal, such as silver or gold. Methods for the production of nanoparticles are well-known in the art and include sol-gel processes. The nanoparticles may have a medium diameter of about 1 to about 100 nm, such as 10, 20, 30, 40, 50, 60, 70, 80, or 90 nm. If gold nanoparticles are used, these may be stabilized, for example by citrate. The nanoparticles may be located on a surface and/or attached or adhered thereto. Alternatively, the surface may be an electrochemically roughened silver surface.
The compounds, i.e. the Raman receptors, which are attached to the substrate can be covalently bound, attached via electrostatic attraction or hydrophobic interaction. "Covalently bound" relates to an attachment on the surface via a covalent bond between at least one atom of the compound and at least one atom of the surface. "Electrostatic attraction" relates to attachment via salt bridges, hydrogen bonds and polar interactions, for example if the surface is charged negative and the compound bears a positive charge or vice versa. "Hydrophobic interaction" includes the interaction between uncharged and non-polar groups.
In the method of the present invention, the surface enhanced Raman signal of the compound can be correlated with the amount of the analyte in the sample.
"Correlation", as used in the context of the present invention, means that the change of the SERS signal due to the binding of the analyte depends on the amount of the analyte. This correlation allows quantifying the amount of analyte. Depending on the compound used, the change of the SERS signal may be a change in intensity of certain bands and/or a shift in the peak wave numbers.
The method is suitable for the detection of an analyte in vivo, as the structures necessary for carrying out the method can be implemented on a biosensor. Alternatively, the analyte may be contained in a sample and the detection is in vitro. In any case, the method according to the invention allows detection of the analyte in a bodily fluid. This bodily fluid may be selected from the group consisting of plasma, serum, blood, lymph, liquor and urine.
The analyte to be detected according to the invented method is a monosaccharide or an a-hydroxy acid. The monosaccharide may be an aldose or ketose and can be selected from the group consisting of trioses, tetroses, pentoses, hexoses and heptoses. Exemplary monosaccharides include, but are not limited to, glucose, galactose, fructose, mannose, glyceraldehyde, dihydroxyaceton, erythrose, threose, erythrulose, ribose, arabinose, xylose, desoxyribose, ribulose, xylulose, and talose. Also encompassed by the term "monosaccharide" as used herein are sugar alcohols such as mannitol and sorbitol, sugar acids, such as glucuronic acid and galacturonic acid, or derivatives of monosaccharides, such as N-Acetyl-D-glucosamine and glucosamine. The term includes all stereoisomers, in particular the D- and the L-form and the a- and β -configuration. Exemplary monosaccharides include, but are not limited to: a-D-glucose, β-D-glucose, a-D-galactose and β-D-galactose. Preferably the monosaccharide to be detected is glucose, more preferably D-glucose, even more preferably a-D-glucose.
Also detectable according to the methods of the invention are a-hydroxy acids, including, but not limited to, glycolic acid, lactic acid, citric acid, mandelic acid, malic acid and isocitric acid.
The analyte may be free in solution, either in a cell or in a bodily liquid. Alternatively, the analyte may be attached to another substance, including proteins, lipids, DNA, RNA and cells. In one embodiment, the analyte may be attached to a protein, in case the analyte is a monosaccharide thus forming a glycosylated protein. Glycosylated proteins typically comprise the following monosaccharides: N-acetyl glucosamine, mannose, fructose and galactose. By detecting these saccharides, the method of the invention also allows to detect glycosylated proteins. The glycosylated protein may be located at the outer surface of a cell or be present in a bodily fluid. Some analytes, such as monosaccharides, in particular glucose, a-hydroxy acids or glycosylated proteins, are more or less abundant in a patient with a certain disease, disorder or physical state and are thus indicators of the disease, disorder or physical state. Exemplary diseases include, but are not limited to diabetes, obesity, inflammation and cancer. Exemplary physical states include, but are not limited to hypo- and hyperglycemia. Accordingly, the methods of the invention allow monitoring an analyte which is an indicator and/or marker of these diseases/physical states in a patient. The methods allow diagnosing these diseases, disorders and physical states and establishing a prognosis. For example, the amount of glucose detected in a patient or in a patients sample may serve as an indicator of diabetes, hyper- or hypoglycemia. Alternatively, the method allows monitoring the treatment of a disease using the amount of analyte as an indicator. In patients suffering from diabetes the amount of detected analyte may indicate the need of an insulin treatment or confirm the efficiency of the insulin treatment. In patients suffering from cancer, such as prostate cancer, detection of an increased or decreased level of a specific analyte, such as a glycosylated protein, may be useful for diagnostic purpose. One analyte suitable for the diagnosis of prostate cancer includes the serum glycoprotein prostate-specific antigen.
A patient, as defined herein, is an animal, including mammals, in particular a human being.
The substrate with the attached Raman reporter compounds may also be integrated into cells. Hence, the method of the present invention also allows detecting an intracellular
analyte. The SERS signal of the compound may be generated by a laser pointing to the cell, fluorescence microscope, a confocal microscope, or an optical fiber reaching to the cell. A confocal microscope may generate the SERS signal in a defined cell compartment. Thus, the analyte may be detected in a particular cell compartment. Deviation from the analyte level under control conditions may allow drawing conclusions about the state of the cell. Low or high glucose levels may indicate cell stress, in particular oxidative stress. Alternatively, the detected analyte may serve as an indicator of apoptosis. Cell compartments comprise the cell membrane, the cytoplasm, the ER, the Golgi apparatus, lysosomes, the nucleus, endosomes, lysosomes, mitochondria, chloroplasts and vacuoles.
In other embodiments, the method may be used in a FACS-based cell sorting assay. Cells comprising the analyte or cells with a certain level of analyte may be separated from each other into different vessels.
The transfer of substrates comprising Raman receptors into cells may be achieved by coupling to antibodies, liposome based transfection agents, coupling to or co- administration with protein transduction domains, co-administration with pore- forming agents, endocytosis, or electroporation.
In the methods of the invention, the compound, i.e. the Raman receptor, to be used in the method is attached to the substrate surface via electrostatic, hydrophobic or covalent interactions. In various embodiments of the methods of the invention, the compound is a phenyl boronic acid derivative, pyridyl boronic acid derivative or a bipyridyl boronic acid derivative. In preferred embodiments, the compound is a phenyl boronic acid derivative, i.e. a compound including a phenyl ring substituted with a boric acid group. Preferably the compound also includes a heteroaryl group coupled either directly or via a linker group to the phenyl boronic acid. In one specific embodiment, the compound is a boronic acid substituted benzyl viologen, for example a bis(phenyl boronic acid) viologen, or a purinyl phenyl boronic acid, such as a 3- or 4-(purin-9-ylcarbonyl)phenyl
boronic acid. "Viologen" in this context relates to a bipyridinium core structure, wherein the pyridinium rings are coupled to each other by a 3,3'-, 3,4'- or 4,4'- bond.
In order to facilitate covalent coupling of the compound to the substrate surface, in particular a metal surface, the compounds can include a linker group. A preferred linker group is a linker comprising a thiol (-SH) group. The thiol group may facilitate covalent attachment to the metal surface by forming a covalent bond between the sulfur atom and a metal surface atom. The terms "thiol group" and "mercapto group" are used interchangeably herein and both relate to the -SH group. The linker may comprise an alkenyl or ethylene glycol chain, for example an ethylene glycol of the formula -(O- CH2-CH2)n- , wherein n is an integer from 1 to 10, or an alkenyl group of formula - (CH2)P-, wherein p is an integer from 1 to 20.
In other embodiments of the method, the compound is positively or negatively charged and attached to the substrate surface by electrostatic interactions or the compound is hydrophobic and attached to the substrate surface by hydrophobic interactions. The compounds undergoing electrostatic interaction with the substrate may have a bipyridinium core due to its intense SERS response and the ease of functionalization by alkyl halides via quarternization to form a viologen. Boronic acid substituted benzyl viologens (See Figures 2 and 10) are particularly useful as SERS reporters for monosaccharide, in particular glucose, detection. SERS signal modulation occurs when the analyte binds to the boronic acid receptor moiety, which at pH 7.4 and in the absence of glucose exists in its trigonal neutral form. In the presence of glucose, the formation of the more-acidic glucose boronate ester shifts the acid-base equilibrium of the boronic acid towards its anionic tetrahedral "-ate" form, causing electronic and/or steric changes. These changes in the molecular structure can cause a significant change in the orientation and the distance of the molecule from the nanoparticle surface leading to a change in the SERS intensity of the molecular core. In a SERS platform for analyte, e.g. glucose, sensing under physiological conditions, such an approach leads to an added advantage over a fluorescent dye based approach or quantum dot based in terms of increased sensitivity coupled with the avoidance of problems such as photo bleaching, broad emission profiles and peak overlapping. Moreover, the SERS substrate
based approach is easy to transfer into a fiber mode and allows to reduce toxicity issues due to the use of noble metal based, e.g. gold based, substrates (compared to the toxic fluorescent quantum dot based approach) that can be incorporated into a minimally invasive implantable device. The multiplexing capability of SERS provides another advantage both, in context of sensing experiments to understand complex mechanistic pathways in biological studies and personalized medicine.
The putative mechanism of SERS based monosaccharide sensing is illustrated by benzyl boronic acid viologen (BBV1) and using a SERS substrate that is fabricated with citrate stabilized gold nanoparticles (cf. Figure 2). Since the gold nanoparticle surface is negatively charged, the positively charged BBV1 can strongly adsorb on the substrate to due to electrostatic interactions. Moreover, the boronic acids groups in BBV1 can form a boronate complex with the citrate leading to the immobilization of the BBV1 molecule on the surface which provides a strong SERS signal upon laser excitation. Upon competitive binding of the analyte, e.g. glucose, to the receptor at the surface, the analyte-receptor complex can produce an increase in SERS intensity due to the steric and electronic changes that follow the binding event. The negative charge associated with the boronate complex that forms upon glucose binding to BBV1 leads to a change of the orientation of the molecule relative to the surface leading to a higher SERS signal.
Surprisingly, the inventors of the present invention have found out that BB VI, compared to the SERS active compound crystal violet, induces much smaller variations of the signal intensity on the substrate, probably due to the symmetric bis positive charge and the bis boronic acid groups that bind tightly on the surface of gold nanoparticle, leading to a more thermodynamically stable surface complex. Hence, the compounds of the present invention allow for more accurate analyte detection due to smaller signal variations. Compounds useful as Raman reports in the invented methods include, but are not limited to:
N,N'-Bis-(benzyl-3 -boronic acid)-[3,4']bipyridiniurn Dibromide (3,4'-w-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-p-BBV);
N,N'-Bis-(benzyl-3-boronic acid)-[3,3']bipyridinium Dibromide (5,3 -w-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-q-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-/?-BBV);
N,N'-Bis-(benzyl-3-boronic acid)-[ ,4']bipyridinium Dibromide (4,4'-m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-p-BBV);
3-(6-Mercaptopurin-9-ylcarbonyl)phenylboronic acid;
4-(6-Mercaptopurin-9-ylcarbonyl)phenylboronic acid;
2-((3-Mercaptoethylcarbonyl)amino)-5-pyridyl boronic acid;
Pyrene-l-boronic acid; and
Benzothiophene-2-boronic acid. Depending on whether the above bipyridinium, pyrene and benzothiophene compounds are to be attached by covalent bonds or not, they may comprise an additional linker group as defined above, which, in case of the viologen compounds, may be attached to the bipyridinium core. In other embodiments of the above compounds, the bipyridinium compounds can be used as other salts not limited to the bromide salt, such as, for example, other halogen salts like fluoride, chloride or iodide salts.
In other embodiments of the above compounds, the purinyl compounds lack the mercapto group and are attached to the substrate by another linker group as defined above or by electrostatic or hydrophobic interactions.
In another aspect, the present invention relates to a biosensor for the detection of an analyte using surface-enhanced Raman spectroscopy, comprising a plurality of nanoparticles, wherein one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives are attached to the nanoparticle surface.
In these biosensors of the invention, the nanoparticles, the compounds or both can be as defined above in connection with the methods of the invention. Similarly, the analytes to be detected can be the same as those that have been defined above. Specifically, the analytes include monosaccharides, such as glucose, and alpha-hydroxy acids. In one specific embodiment of the biosensor, the biosensor is configured for quantitative detection of glucose in a physiological concentration range.
The biosensor can comprise a substrate to which the nanoparticles are adhered. Adherence may be achieved by any means, including covalent bonding, electrostatic or hydrophobic interactions. The attachment of the nanoparticles to the sensor surface may have the form of a coating, including a uniform coating or in form of spots.
In various embodiments, the biosensor is configured for in vivo and/or in vitro use.
In a further aspect, the present invention relates to compounds that are of use as Raman reporters for certain analytes and are thus useful in the methods of the invention. The compounds contemplated by the present invention are compounds of general Formula I
Formula I
wherein
A is heteroaryl and comprises at least one nitrogen atom,
L is a linker selected from the group consisting of -C(O)-, -C(0)-0-, -(CH2)m-, - C(=CH2 , -C(0)-NH-, -NH-C(O)-, -0-, -S-, =CH- and -CH=, wherein m is an integer from 1 to 3;
L2 is a linker selected from the group consisting of a direct bond between A and SH, - C(0)-0-(CH2)q-, -C(0)-S-(CH2)q-, -(CH2)p-, -C(0)-S-(0-CH2-CH2)n-, -C(0)-S -(CH2-
CH2-0)n-, -C(0)-S -(CH2-CH2-0)„-(CH2)q- and -C(0)-S -(0-CH2-CH2)n-(CH2)q-, wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and q is an integer
B is aryl;
and salts thereof.
The salts of the compounds of the invention include all possible salts, in particular halogen salts. If the compounds comprise quaternary nitrogen atoms, the anion may be selected from fluoride, chloride, bromide and iodide, preferably bromide.
In specific embodiments of the invention, A comprises at least 1, at least 2, 3, 4 or more nitrogen atoms. Also contemplated is that A is an heteroaryl group consisting of two or more aromatic rings that may be condensed or directly coupled to each other. In various embodiments of the invention, A is selected from the group consisting of purinyl, indolyl, pyridinyl, bipyridyl, pyrimidinyl, azaindolyl, pyrrolyl, pyrazinyl, pyridazinyl, isoindolyl, benzimidazolyl, imidazolyl, indazolyl, chinolinyl, isochinolinyl, acridinyl and benzothiophenyl. Preferably, A is selected from the group consisting of pyridinyl, bipyridinyl and purinyl. B can be any aryl group, including aryl groups consisting of 1, 2 or more rings that can either be condensed or covalently coupled. In specific embodiments, B is selected from phenyl or naphthyl, preferably phenyl.
In one embodiment of the above compounds L is carbonyl -C(O)-. In one embodiment of the compounds of the invention, wherein L is -C(O)-, A is purinyl, L2 is a direct bond and B is phenyl, thus forming mercaptopurinylcarbonyl phenyl boronic acids or salts thereof. In alternative embodiments thereof, L2 is -(CH2)P-.
In one embodiment, the compounds are of Formula II:
Formula II.
In these compounds, the boric acid group can be in the o-, m- or p-position relative to the carbonyl group, preferably in the m- or p-position. The mercapto group can be in the 2-, 6- or 8-position of the purinyl ring, preferably in the 2- or 6-position.
In other embodiments of the compounds of the invention, L is -(CH2)m-. In these compounds, wherein L is -(CH2)m-, A can be purinyl, L2 can be a direct bond and B can be phenyl, thus forming mercaptopurinyl benzyl boronic acids or salts thereof. In alternative embodiments thereof, L2 is -(CH2)P-.
In certain embodiments of these compounds, the compounds are of Formula III:
In these compounds of Formula III, the boric acid group can be in the o-, m- or p- position relative to the carbonyl group, preferably in the m- or p-position. The mercapto
group can be in the 2-, 6- or 8-position of the purinyl ring, preferably in the 2- or 6- position.
In further embodiments of the compounds of general Formula I, A is bipyridyl, L is -(CH2)m-, L2 is -(CH2)P-, B is phenyl. Also included are salts of these compounds, in particular halogen salts, preferably bromide salts.
Preferably, A is bipyridyl, wherein both nitrogens are in the quaternary state, L is - (CH2)m-, L2 is -(CH2)p-, B is phenyl and the compound is a halogen salt. More preferably, the compound is of formula IV:
Formula IV wherein X" is chloride, bromide, iodide or fluoride. The boric acid substituent may be in the m- or p-position of the phenyl ring.
In still further embodiments, the invention relates to compounds of Formula V:
Formula V
wherein X" is chloride, bromide, iodide or fluoride and D is selected from the group consisting of -(CH2)P-, -(0-CH2-CH2)n-, -iCH2-CH2-0)n-, -(CH2-CH2-0)n-(CH2)m- and -(0-CH2-CH2)n-(CH2)m-, wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and m is an integer from 1 to 5.
In one embodiment thereof, the compound is a compound of Formula VI
Formula VI
wherein X" is chloride, bromide, iodide or fluoride and n is an integer from 1 to 10.
In the compounds of Formula V or VI, the pyridyl rings can be connected such as to form a 3,4'-, 4,3'-, 3,3 '- or 4,4'-bipyridyl structure. In these compounds, the bipyridyl benzyl boronic acid moiety may be selected from the group consisting of:
N,N'-Bis-(benzyl-3-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-m-BBV);
N,N'-Bis-(benzyl-2 -boronic acid)-[3,4']bipyridinium Dibromide (3,4'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,4']bipyridinium Dibromide (3,4'- ?-BBV);
N,N'-Bis-(benzyl-3 -boronic acid)-[3,3']bipyridinium Dibromide (3,3'-m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-o-BBV);
N,N'-Bis-(benzyl-4-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-p-BBV);
N,N'-Bis-(benzyl-3-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-m-BBV);
N,N'-Bis-(benzyl-2 -boronic acid)-[ ,4']bipyridinium Dibromide (4,4'-o-BBV); and
N,N'-Bis-(benzyl-4-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-p-BBV);
Further preferred embodiments of these compounds are the compounds, wherein the -C(0)-S-(CH2-CH2-0)„-CH2-SH or the -C(0)-S-D-SH group is in the m-position relative to the nitrogen atom of the pyridine ring. All the above compounds of the invention are useful as Raman reporters in the SERS technique, in particular the SERS-based detection methods of the invention.
Therefore, the present invention also covers the above-described methods of the invention, wherein the compounds used in these methods for analyte binding and detection are those defined above, i.e. the compounds of the invention. Similarly, in various embodiments of the biosensors of the invention, the compounds used as Raman reporters are those defined above.
In a further aspect, the present invention also relates to an optical fiber comprising a biosensor as detailed-above. The optical fiber may facilitate in vivo detection of the analyte and may be used for this purpose, for example in a method for the diagnosis of a disease by means of detecting the analyte in vivo. Alternatively, the optical fiber may be used for the detection of an analyte in vitro. In any case, the analyte may be a monosaccharide, in particular glucose, or an a-hydroxy acid.
The above compounds of the invention are also contemplated for use as a monosaccharide, in particular glucose, or a-hydroxy acid receptor. The invention thus also covers methods for the detection of a monosaccharide, in particular glucose, or an α-hydroxy acid by using any of the compounds of the invention as a reporter.
Examples
Example 1 : Synthetic protocols
Synthesis of N.N'-Bis-Cbenzylboronic acidV[4,4,1bipyridinium Dibromides
General Procedure: A mixture of 4,4'-bipyridine (0.5 g, 3.2 mmol) and bromomethyl- phenylboronic acid (0.47 g, 3.8 mmol) in DMF (5 ml) was heated at 80 °C for two days. On completion of the reaction, it was cooled to 0 °C and mixed with acetone to precipitate the product. The precipitate was filtered off and washed with acetone (3 x 25 ml) to remove excess DMF. The resultant solid was dried and lyophilized to afford the N,N'-Bis-(benzylboronic acid)-[4,4']bipyridinium Dibromide. Yield l.lg (85 %) In general, the yields of the addition reaction range between 80 - 90 %.
Data:
N,N'-Bis-(benzyl-4-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-para):
1H NMR (300 MHz, CDC13): δ 9.53 (d, J=6.5 Hz, 4H), 9.76 (d, J=6.5 Hz, 4H), 8.18 (s, 4H), 7.85 (d, J=7.8 Hz, 4H), 7.55 (d, J=d, J=7.8 Hz, 4H), 5.96 (s, 4H)
N,N'-Bis-(benzyl-3-boronic acid)-[4,4']bipyridinium Dibromide( 4,4'-meta):
1H NMR (300 MHz, CDC13): δ 9.50 (d, J=6.6 Hz, 4H), 8.74 (d, J=6.6 Hz, 4H), 8.19 (s, 4H), 7.94 (s, 2H), 7.85 (d, J=7.5 Hz, 2H), 7.64 (d, J=7.5 Hz, 2H), 7.44 (t, J=7.5 Hz, 2H), 5.94 (s, 4H)
N,N'-Bis-(benzyl-2-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-ortho):
1H NMR (300 MHz, CDC13): δ 9.32 (d, J=6 Hz, 4H), 8.72 (d, J=6 Hz, 4H), 8.57 (s, 4H), 7.84 (d, J=6.9 Hz, 2H), 7.49-7.45 (m, 4H), 7.33 (d, J=7.2 Hz, 2H), 6.13 (s, 4H).
Synthesis of N,N'-Bis-(benzylboronic acid)-[3.4,lMPyridinium Dibromides General Procedure:
)2
Step-1 :
To a solution of 3-bromopyridine (7.7 g, 0.049 mol) in dioxane (80 ml) pyridine 4- boronic acid (5 g, 0.04 mol) was added followed by the addition of a degassed solution of sodium carbonate (6 ml, 2 M solution) under inert atmosphere. Triphenyl phosphine (2.66 g, 0.01 mol) and Pd(OAc)2 (0.46 g, 2.03 mmol) were added to the reaction mixture and heated to 80 °C for 12 h. The solution was concentrated, mixed with water and extracted using ethyl acetate (2 x 100 ml). The organic layer was washed with water and brine solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude material was recrystallized using an ethyl acetate - hexane mixture to afford 3,4'-bipyridine. Yield 3 g (47 %)
Step-2:
A mixture of 3,4'-bipyridine (1 g, 6.4 mmol) and bromomethylphenylboronic acid (1.37 g, 0.13 mmol) in DMF (10 ml) was heated to 80 °C for two days. On completion of the reaction, the solution was cooled to 0 °C and mixed with acetone to precipitate the product. The precipitate was filtered off and washed with acetone (3 x 50 ml) to remove excess DMF. The resultant solid was dried and lyophilized to afford the N,N'-Bis- (benzyl-boronic acid)-[3,4']bipyridinium Dibromide. Yield 2.2 g (81 %)
In general, the yields of the addition reaction range between 80 - 90 %
Data:
N,N'-Bis-(benzyl-4-boronic acid)-[3,4']bipyridinium Dibromide (3 ,4 '-para):
1H NMR (300 MHz, CDC13): δ 10.14 (s, 1H), 9.55 (d, J=6.3 Hz, 2H), 9.37 (d, J=6 Hz, 1H), 9.23 (d, J=8.1 Hz, 1H), 8.77-8.75 (m, 2H), 8.44-8.39 (m, 1H), 8.17 (s, 4H), 7.87- 7.82 (m, 4H), 7.60- 7.54 (m, 4H), 6.01 (s, 2H), 5.96 (s, 2H)
N,N'-Bis-(benzyl-3-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-meta):
1H NMR (300 MHz, CDC13): δ 10.07 (s, 1H), 9.52 (d, J=6.9 Hz, 2H), 9.34 (d, J=6 Hz, 1H), 9.22 (d, J=8.1 Hz, 1H), 8.74 (d, 3=6.9 Hz, 2H), 8.44-8.39 (m, 1H), 8.19 (s, 2H), 8.16 (s, 2H), 7.94 (s, 2H), 7.86-7.82 (m, 2H), 7.63-7.60 (m, 2H), 7.47-7.39 (m, 2H), 5.98 (s, 2H), 5.95 (s, 2H)
N,N'-Bis-(benzyl-2-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-ortho):
1H NMR (300 MHz, CDC13): δ 9.31 (s, 1H), 9.21 (d, J=8.1 Hz, 2H), 9.1 1 (d, J=6.3 Hz, 1H), 8.74 (d, J=6.6 Hz, 1H), 8.70-8.53 (m, 6H), 8.39-8.34 (m, lH), 7.86-7.81 (m, 2H), 7.52-7.32 (m, 6H), 6.16 (s, 2H), 6.14 (s, 2H)
Synthesis of N,N'-Bis-(benzylboronic acidV[3.3'1bipyridinium Dibromides
Step-1 :
To a solution of 3-bromopyridine (5 g, 0.032 mol) in dioxane (50 ml) pyridine 3- boronic acid (5.43 g, 0.044 mol) was added, followed by the addition of a degassed solution of sodium carbonate (6.7 g, 2M solution) under inert atmosphere. Triphenyl phosphine (2.48 g, 0.009 mol) and Pd(OAc)2 (0.7 g, 0.003 mol) were added to the reaction mixture and heated to 80 °C for 12 h. The reaction mix was concentrated; water was added and extracted using ethyl acetate (2 x 100 ml). The organic layer was washed with water and brine solution, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude material was recrystallized using an ethyl acetate - hexane mixture to afford 3,3'-bipyridine. Yield 2 g (41 %)
Step-2:
A mixture of 3,3'-bipyridine (0.5 g, 3.2 mmol) and bromomethylphenylboronic acid (0.47 g, 3.8 mmol) in DMF (20 ml) was heated to 80 °C for two days. On the completion of the reaction, the mixture was cooled to 0 °C and mixed with acetone to precipitate the product. The precipitate was filtered off ahd washed with acetone (5 x 25 ml) to remove excess of DMF. The resultant solid was dried and lyophilized to afford the N,N'-Bis-(benzylboronic acid)-[3,3']bipyridinium Dibromide. Yield 1.2 g. (87 %). In general, the yields of the addition reaction range between 80 - 90 %
Data:
N,N'-Bis-(benzyl-4-boronic acid)-[3,3']bipyridinium Dibromide (3,3 '-para):
1H NMR (300 MHz, CDC13): δ 9.99 (s, 2H), 9.33 (d, J=6 Hz, 2H), 9.11 (d, J=8.1 Hz, 2H), 8.45- 8.40 (m, 2H), 8.17 (s, 4H), 7.84 (d, J=7.6 Hz, 4H), 7.57 (d, J=7.6 Hz, 4H), 5.97 (s, 4H)
N,N'-Bis-(benzyl-3-boronic acid)-[3,3']bipyridinium Dibromide(3,3'-meta):
1H NMR (300 MHz, CDC13): δ 10.03 (s, 2H), 9.33 (d, J=6 Hz, 2H), 9.14 (d, J=6.6 Hz, 2H), 8.46- 8.41 (m, 2H), 8.16 (br s, 4 H), 7.84 (d, J=7.5 Hz, 2H), 7.68 (d, J=7.8 Hz, 2H), 7.45-7.40 (m, 2H), 5.98 (s, 4H) N,N'-Bis-(benzyl-2-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-ortho): 1H NMR (300 MHz, CDC13): δ 9.8 (s, 2H), 9.08 (d, J=6.9 Hz, 4H), 8.57 (br s, 4H), 8.38 (t, J=6.9 Hz, 2H), 7.84 (d, J=7.8 Hz, 2H), 7.51-7.42 (m, 4H), 7.31 (d, J=7.2 Hz, 2H), 6.15 (s, 4H).
Example 2: Nanoparticle work: General protocols
All the glass wares were rinsed in aqua regia (nitro hydrochloric acid) and washed thoroughly with water and ethanol and oven dried before using them. The sodium citrate and gold chloride were obtained from Sigma Aldrich. The gold nanoparticles were prepared by the citrate reduction of HAuCl4. The UV spectral experiments were carried using a Hitachi-9820 spectrophotometer. The TEM measurements were carried out using a JEOL 2010 transmission electron microscope. Example 3: Synthesis of gold nanoparticles
Gold nanoparticles were prepared according to the reported protocols with the following changes. 25mg of hydrogen tetrachloroaurate (III) hydrate powder was added to 200ml
of distilled water and the mixture was brought to rolling boil on a hot-plate with vigorous stirring. Afterwards, about 34.2 mg of sodium citrate dehydrate powder dissolved in 3ml of distilled water were rapidly added to the stirred tetrachloroaurate solution. The mixture was further boiled for 10 minutes, during which the solution exhibited several color changes starting with yellowish then purplish and finally ruby- red. The final solution was stored at 4°C until needed.
Example 4: Substrate fabrication using chemisorption of gold nanoparticles
Microscope glass slides were cut into squares ( =4cm x 1cm) and were immersed in freshly prepared Piranha solution for 1 hour. The slides were then rinsed several times with distilled water and finally with ethanol three times and blow dried using a stream of Argon gas. These slides were then treated with a 1% solution of 3- Mercaptopropyltrimethoxy-silane solution (3MP-TMS) in hexane for 2 hours in a mechanical shaker (180 rpm) at room temperature. The soaked glass squares were incubated in a sealed glass bottle containing 1% 3MP-TMS solution. The glass slides were then washed several times with anhydrous ethanol and water respectively and dried under a stream of Argon gas. Each of the resulting 3MP-TMS treated glass slides was then put into an individual scintillation vial and treated with 10ml of Au nanoparticle solution for 24 hours to obtain the SERS substrate. These substrates were then removed from the nanoparticle solution and washed with water and stored in a dry box until use. Field Emission Scanning Electron Microscopy (FESEM) Measurements of each batch of the substrates were carried out in scanning electron microscope (JEOL, SEM6340F) to examine the surface morphology. Example 5: SERS instrumentation and measurement
Raman and SERS measurements were carried out in a Renishaw In Via Raman (UK) microscope system with an excitation laser at 633 nm. The laser intensity was set to 100% laser power. The laser beam focused on the sample, after passing through the objective lens, had a power of about 6.2 mW. The Raman system was connected to a Leica microscope, wherein the laser light was coupled through a 50 X 0.75 N.A objective lens, which was used to excite the sample and also to collect the returning Raman signal. The detector to collect Raman signals was a Peltier cooled CCD. The
WiRE 3.0 software package (provided with the Renishaw system) was used for instrument control and data acquisition. A 1800 1/mm grating was chosen for the spectral measurement with a resolution of about 1 cm-1. Before each set of measurements the system was calibrated with a silicon standard (520cm_1).
Example 6: SERS glucose reporters
A bipyridinium compound (N,N'-Bis-(benzyl-3-boronic acid)-[4,4']bipyridinium Dibromide (¥,4'-/w-BBV; BBV1)) was chosen as a reporting moiety for glucose sensing due to its intense SERS signal and ease of chemical functionalization by alkyl halides via quarternization of the nitrogen atoms to form viologens. Initial studies to evaluate the interaction of BBV1 with gold nanoparticles were carried out using UV visible spectroscopy and Transmission electron microscopy. Figure 3 shows the UV spectrum of gold nanoparticles in the presence and absence of BBV1. The BBV1 absorption peak was around 280 nra (Figure 3) and did not interfere with the gold absorption at 520 nm. Upon the addition of BBV 1 to the gold nanoparticle solution, an additional peak appeared around 800 nm. Upon further successive addition, the intensity at the 520 nm peak decreased and the additional peak underwent a red shift, indicating that BBV1 caused the aggregation of the gold nanoparticles. A 2D substrate array was prepared, consisting of approximately 40 nm gold nanoparticles on a modified glass support. The glass surface was modified by thiol groups (Figure 4) and chemisorption of the nanoparticles carried out using citrate stabilized gold nanoparticles (C-Au) synthesized by the Turkevich method (Kimling et al. J. Phys. Chem. B 2006, 110, 15700-15707). The C-Au substrate was incubated with 1 μΜ of BBV1 in pH=7.4 PBS and produced a surface layer of adsorbed BBVl molecules as evidenced by the stable SERS spectrum of BBVl (Figure 4). Whereas 1 μΜ BBVl alone did not produce a significant Raman signal, upon incubation of BBVl with the C-Au substrate, instantly a strong SERS signal was detected (Figure 4c) that correlates with the Raman spectra of BBVl in powder form (Figure 4d).
It was found that the detection of an SERS signal from the substrate required the treatment of the gold nanoparticles with a BBV 1 solution of an at least nanomolar
concentration. Further experiments were performed which showed that the glucose binding to the sensor does not produce any considerable wave number shift in the SERS spectrum but rather produces an increase in the peak intensity. The SERS spectrum shows strong vibrational bands that can be followed for glucose sensing applications.
Since 2D nanoparticle array types of SERS substrates such as C-Au substrate were known to exhibit large point to point variations in signal intensity, optimizations of the array fabrication were carried out to reduce the variation to 5% of the average SERS intensity for a known strongly Raman active molecule, such as crystal violet on a given batch of substrate. It was noted that, compared to crystal violet, BBVl induced much smaller variations of the signal intensity on the substrate, probably due to the symmetric bis positive charge and the bis boronic acid groups that bind tightly on the surface of gold nanoparticle, leading to a more thermodynamically stable surface complex. Example 7: Glucose Detection
The glucose sensing experiments on the produced SERS substrate were carried out, first by incubating the substrate with ΙμΜ BBVl for 12 hours, followed by 30 minute incubation with glucose in a physiological range of concentrations (0-25 mM) in pH=7.4 PBS. The SERS intensity from these substrates was recorded for 10 seconds using 633 nm at a maximum laser power of 6.2 mW. A large number of glucose sensing experiments were carried out and the spectral data from a typical experiment under physiological conditions are shown in Figure 5. The BBVl SERS spectrum shows an increase in intensity that is proportional to the increase in glucose concentration. All the peaks of the BBVl SERS spectrum show a varying degree of sensitivity to glucose concentrations. The most representative peaks at six different wave numbers were followed for glucose response and demonstrated the possibility to apply the detection in a multiplexing or ratiometric approach. The glucose sensing profiles for the four major peaks are shown in Figure 6. Example 8: Optimization for low glucose levels
The glucose sensing data from Figure 6 indicates that the used configuration the SERS system was more sensitive to the higher end of the physiologically relevant
concentration, i.e. 10-25 mM. In order to change the sensitivity to lower glucose concentrations, the amount of BBVl adsorbed to the nanoparticle surface was increased. Then the measurements were carried out again and the obtained data showed that the sensitivity of the assay was shifted to the lower end of the tested glucose concentrations. Figure 7 depicts the glucose sensing experiment, wherein the 1620 cm"1 peak intensity in the SERS spectrum was followed at different BBVl concentrations (left graph: 1 μΜ BBVl 12 h; right graph: 1 mM BBVl). The obtained results clearly demonstrate the advantages of this two component (receptor molecule-nanoparticle) approach that allows tuning the sensitivity of the SERS assay to the desired range.
Example 9: Mechanism of glucose detection
In order to investigate the mechanism of glucose sensing, bipyridine salts that lack the boronic acid moiety (4,4'-BV; 3,4'-BV and 3,3 '-BV; Figure 8) were synthesized and subjected to glucose sensing conditions. As expected, there was no glucose response when any of these compounds was used for the SERS-based glucose detection. The SERS spectrum was not significantly changed upon a systematic change in glucose concentration.
Example 10: BBV compounds for the detection of glucose
All possible isomers of BBVl were synthesized to evaluate the glucose sensibility and glucose selectivity of this class of Raman reporter molecules. Figure 9 shows all 9 possible isomers of bipyridinium boronic acids. All of these isomers showed an intense SERS spectrum (Figure 10) and are thus suitable for glucose detection and glucose selectivity experiments. The isomer 3,4'-o-BBV on a SERS substrate had excellent selectivity and dynamic range for glucose and was therefore tested in further glucose sensing experiments.
Example 11 : 3,4'-o-BBV for the detection of glucose
3,4'-o-BBV was used for glucose sensing experiments on the produced SERS substrate, first by incubating the substrate with 1 μΜ 3,4'-o-BBV for 12 hours, followed by 10 minute incubation with glucose in the concentration range of 0-100 mM in pH=7.4 PBS in flow cell configuration. The SERS intensity from this substrate was recorded for 10
seconds using 633 nm at a maximum laser power of 0.62 mW. Figure 11 shows the glucose response of 3,4'-o-BBV SERS spectrum peak at 1620 cm-1.
Example 12: Hydrophobic SERS glucose sensors
The experiments were focused on high cross section aromatic boronic acids which can bind with gold nanoparticles via hydrophobic interactions. The molecules bound to the nanoparticle surface (nanoparticle-glucose reporter complex) can be further stabilized by thiolated PEG/small molecule encapsulation to allow their use in biosensing. Upon glucose binding to the receptor, a boronate ester is formed which leads to a change in the SERS spectrum of the nanoparticle-reporter complex that can be monitored spectroscopically. Two representative examples of these molecules that allow the SERS-based glucose detection are shown in Figure 12. Compounds of this class are insoluble in aqueous media. However, suitable experimental conditions allowing their immobilization on citrate stabilized gold nanoparticles were identified. These conditions comprise the incubation of a solution of the compound with dimethyl sulfoxide (DMSO). After incubation, the reporter attached nanoparticles were centrifuged to remove the excess reporter and were functionalized with PEG or mercapto propionic acid to impart buffer stability. Interestingly, the mercapto propionic acid stabilized particles showed an efficient immobilization of the two compounds pyrene-l-boronic acid and thionaphthene boronic acid. The SERS spectra of the compounds are shown in Figure 13. The glucose response of the SERS spectrum (peak wave number shift) from the mercapto propionic acid stabilized gold nanoparticles, which were adsorbed with thionaphthene boronic acid is shown in Figure 14. This is a representative example for glucose detection with compounds of this category. The experiment clearly demonstrates that also by hydrophobic interactions the glucose reporter can be immobilized on a gold nanoparticle surface and can be utilized for glucose sensing.
Example 13: Covalentlv bound SERS glucose sensors
4-(6-Mercaptopurin-9-ylearbonyl)phenyl boronic acid and 3-(6-Mercaptopurin-9- ylcarbonyl)phenyl boronic acid were covalently anchored via their mercapto groups on the surface on the produced SERS substrate by incubating the substrate with 1 μπι of a solution of 4-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid or 3-(6-
Mercaptopurin-9-ylcarbonyl)phenyl boronic acid in ethanol overnight. Thereafter the substrate was washed with ethanol several times to remove the non-covalently bound molecules and used in glucose sensing in a flow cell configuration as in the experiment of 3,4'-o-BBV. The SERS spectrum of these compounds is shown in Figure 15 (A: 4- (6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid; B: 3-(6-Mercaptopurin-9- ylcarbonyl)phenyl boronic acid) and the glucose response of the SERS intensity of the peak at 1001 cm-1 of 4-(6-Mercaptopurin-9-ylcarbonyl)phenyl boronic acid in a flow cell experiment where glucose concentration was systematically varied is shown in Figure 16.
Example 14: Fiber optic probe
An exemplary design of a fiber optic probe according to the invention is schematically shown in Figure 17. Such a device may be used in in vitro diagnostics or in a minimal invasive in vivo setup.
Example 15: SERS glucose sensing
Six pieces of SERS substrates were incubated with ImM BBV1 solution overnight. Afterwards, the substrates were removed from the BBV1 solution and rinsed one time with 10 mL of deionized water. The substrates were then removed from the glucose solution and placed on glass a glass microscopic slide with a cover glass. The SERS spectra of all the substrates were recorded using a 633 nm laser, as described above, with 10 second acquisition time. For each substrate the SERS spectrum was recorded at 8 different points, collecting three different accumulations at each point. Each of the BBV1 treated and SERS analyzed substrates was then immersed in 2ml glucose solutions of the following concentrations 0, 5mM, lOmM, 15mM, 20mM and 25mM in PBS for 30 minutes. The substrates were then removed from the glucose solution and placed on a glass microscopic slide with a cover glass. The SERS spectra from these substrates were recorded at eight different points, wherein for each point an average of three spectra was calculated.
Example 16: Synthesis of N SP-Bis-fbenzylboronic acid")-f4.4,1 bipyridinium (polyethylene glycol thioalkyl thioester Dibromides
The general scheme:
Step a:
To a solution of 3-bromo nicotinic acid ethyl ester in p-dioxane is added pyridine 3- boronic acid followed by the addition of degassed solution of sodium carbonate under inert atmosphere. Triphenyl phosphine and Pd(OAc)2 are added to the reaction mixture and heated at 100 °C for 12 h. The reaction mixture is concentrated, combined with water and extracted using ethyl acetate (2 x 100 ml). The organic layer is washed with water and brine solution, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude material is recrystallized using ethyl acetate -hexane mixture to afford ethyl 5-pyridin-3-ylpyridine-3-carboxylate.
Step b:
5-pyridin-3-ylpyridine-3-carboxylate is dissolved in THF. To the solution concentrated HC1 is added and the solution boiled under reflux.
Step c:
To the solution of Step b thionyl chloride is added and the solution further boiled under reflux.
Step d:
For the formation of the thioester derivative, the compound of step c is mixed with the corresponding bis-thiol and under addition of Et3N in methylenchoride as solvent the reaction is stirred for 12 hrs.
Step e:
The corresponding N,N'-Bis-(benzylboronic acid)-[4,4'] bipyridinium (poly)ethylene glycol thioalkyl thioester Dibromide is obtained by mixing the compound of step d and bromomethylphenylboronic acid in DMF (20 ml). The mixture was heated at 80 °C for two days. On completion of the reaction, it was cooled down to 0 °C and added to acetone resulting in the formation of a precipitate. The precipitate was filtered off and washed with further acetone (5 x 25 ml) to remove excess DMF. The resultant solid was dried and lyophilized to afford the desired N,N'-Bis-(benzylboronic acid)-[4,4'] bipyridinium (poly)ethylene glycol thioalkyl thioester Dibromide.
While the invention has been particularly shown and described with reference to specific embodiments, it should be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. The scope of the invention is thus indicated by the appended claims and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced.
All documents cited or referred to are herein incorporated by reference in their entirety.
Claims
1. A method for detecting an analyte using surface enhanced Raman spectroscopy (SERS), comprising
- contacting the analyte with one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives, wherein the one or more compounds are attached to a metal substrate surface that enhances Raman scattering; and
- detecting a surface enhanced Raman signal from said compound.
2. The method of claim 1, wherein the surface enhanced Raman signal of the compound is correlated with the amount of the analyte.
3. The method of claim 1 or 2, wherein the detection is in vivo.
4. The method of claim 1 or 2, wherein the analyte is contained in a sample and the detection is in vitro.
5. The method of any one of claims 1-4, wherein the analyte is detected in a bodily fluid comprising said analyte.
6. The method of claim 5, wherein said bodily fluid is selected from the group consisting of plasma, serum, blood, lymph, liquor and urine.
7. The method of any one of claims 1-6, wherein the analyte 'is a monosaccharide or an a-hydroxy acid.
8. The method of claim 7, wherein the monosaccharide is glucose.
9. The method of any one of claims 1-8, wherein the compound is attached to the substrate surface via electrostatic, hydrophobic or covalent interactions.
10. The method of any one of claims 1-9, wherein the compound is a phenyl boronic acid derivative, pyridyl boronic acid derivative or a bipyridyl boronic acid derivative or a salt thereof.
11. The method of any one of claims 1-10, wherein the compound is a boronic acid substituted benzyl viologen or a salt thereof.
12. The method of any one of claims 1-10, wherein the compound is a 3- or 4- (purin-9-ylcarbonyl)phenyl boronic acid or a salt thereof.
13. The method of any one of claims 1-12, wherein the compound is covalently attached to the substrate surface via a linker.
14. The method of claim 13, wherein the linker comprises at least one thiol group that facilitates binding to the substrate surface.
15. The method of claim 13 or 14, wherein the linker comprises an ethylene glycol of the formula
-(0-CH2-CH2)n- ,
wherein n is an integer from 1 to 10.
16. The method of any one of claims 1-12, wherein the compound is positively charged and attached to the substrate surface by electrostatic interactions.
17. The method of any one of claims 1-12, wherein the compound is hydrophobic and attached to the substrate surface by hydrophobic interactions.
18. The method of any one of claims 1-17, wherein the compound is selected from the group consisting of:
N,N'-Bis-(benzyl-3 -boronic acid)-[3,4']bipyridinium Dibromide (3,4'-m-BBV); N,N'-Bis-(benzyl-2-boronic acid)-[5,4']bipyridinium Dibromide (3,4'-o-BBV); N,N'-Bis-(benzyl-4-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-p-BBV); N,N'-Bis-(benzyl-3 -boronic acid)-[3,3']bipyridinium Dibromide (3,3'-m-BBV); N,N'-Bis-(benzyl-2-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-o-BBV); N,N'-Bis-(benzyl-4-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-p-BBV); N,N'-Bis-(benzyl-3-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-m-BBV);
N,N'-Bis-(benzyl-2-boronic acid)-[4,4']bipyridinium Dibromide (¥,4'-o-BBV); N,N'-Bis-(benzyl-4-boronie acid)-[4,4']bipyridinium Dibromide (¥,4'-/?-BBV);
3- (6-Mercaptopurin-9-ylcarbonyl)phenylboronic acid;
4- (6-Mercaptopurin-9-ylcarbonyl)phenylboronic acid;
2-((3-Mercaptoethylcarbonyl)amino)-5-pyridyl boronic acid;
Pyrene-1 -boronic acid; and
Benzothiophene-2-boronic acid;
and salts thereof.
19. The method of any one of claims 1-18, wherein the substrate is a nanoparticle.
20. The method of claim 19, wherein the nanoparticle is coated with or consisting of a noble metal.
21. The method of claim 20, wherein the noble metal is selected from gold and silver.
22. The method of any one of claims 19-21, wherein the nanoparticle is coated with a silver film.
23. The method of any one of claims 19-22, wherein the nanoparticle. is a citrate-stabilized gold nanoparticle.
24. A biosensor for the detection of an analyte using surface-enhanced Raman spectroscopy, comprising a plurality of nanoparticles, wherein one or more compounds selected from the group consisting of aryl boronic acid derivatives, heteroaryl boronic acid derivatives, aryl boronate derivatives and heteroaryl boronate derivatives are attached to the nanoparticle surface.
25. The biosensor of claim 24, further comprising a substrate, wherein the nanoparticles are adherent to the substrate.
26. The biosensor of claim 24 or 25, wherein the biosensor is configured for in vivo and/or in vitro use.
27. The biosensor of any one of claims 24-26, wherein the analyte is a monosaccharide or an a-hydroxy acid.
28. The biosensor of claim 27, wherein the analyte is glucose.
29. The biosensor of any one of claims 24-28, wherein the biosensor is configured for quantitative detection of glucose in a physiological concentration range.
30. The biosensor of any one of claims 24-29, wherein the one or more compounds are attached to the substrate surface via electrostatic, hydrophobic or covalent interactions.
31. The biosensor of any one of claims 24-30, wherein the one or more compounds are phenyl boronic acid derivatives, pyridyl boronic acid derivatives or bipyridyl boronic acid derivatives or salts thereof.
32. The biosensor of any one of claims 24-31, wherein the one or more compounds are boronic acid substituted benzyl viologens or salts thereof.
33. The biosensor of any one of claims 24-32, wherein the one or more compounds are covalently attached to the substrate surface via an organic linker.
34. The biosensor of claim 33, wherein the organic linker comprises at least one thiol group that facilitates binding to the substrate surface.
35. The biosensor of claim 33 or 34, wherein the organic linker comprises an ethylene glycol of the formula
wherein n is an integer from 1 to 10.
36. The biosensor of any one of claims 24-32, wherein the compound is positively charged and attached to the substrate surface by electrostatic interactions.
37. The biosensor of any one of claims 24-32, wherein the compound is hydrophobic and attached to the substrate surface by hydrophobic interactions.
38. The biosensor of any one or claims 24-37, wherein the nanoparticle is coated with or consisting of a noble metal.
39. The biosensor of claim 38, wherein the noble metal is selected from gold and silver.
40. The biosensor of any one of claims 38-39, wherein the nanoparticle is coated with a silver film.
41. The biosensor of any one of claims 24-40, wherein the nanoparticle is a citrate-stabilized gold nanoparticle.
Formula I
wherein
A is heteroaryl and comprises at least one nitrogen atom,
L is a linker selected from the group consisting of -C(O)-, -C(0)-0-, -(CH2)m-, - C(=CH2)-, -C(0)-NH-, -NH-C(O)-, -0-, -S-, =CH- and -CH=, wherein m is an integer from 1 to 3;
L2 is a linker selected from the group consisting of a direct bond between A and SH, - C(0)-0-(CH2)q-, -C(0)-S-(CH2)q-, -(CH2)P-, -C(0)-S-<0-CH2-CH2)n-, -C(0)-S -<CH2- CH2-0)n-, -C(0)-S -(CH2-CH2-0)n-(CH2)q- and -C(0)-S -(0-CH2-CH2)„-(CH2)q-, wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and q is an integer from 1 to 5;
B is aryl;
or a salt thereof.
43. The compound of claim 42, wherein A is selected from the group consisting of purinyl, indolyl, pyridinyl, bipyridyl, pyrimidinyl, azaindolyl, pyrrolyl, pyrazinyl, pyridazinyl, isoindolyl, benzimidazolyl, imidazolyl and indazolyl.
44. The compound of claim 42 or 43, wherein L is bound to A via the at least one nitrogen atom of the heteroaryl ring.
45. The compound of any one of claims 42-44, wherein B is selected from phenyl or naphthyl.
46. The compound of any one of claims 42-45, wherein L is -C(O)-.
47. The compound of any one of claims 42-46, wherein A is purinyl, L is - C(O)-, L2 is a direct bond and B is phenyl.
48. The compound of any one of claims 42-47, wherein the compound is a compound of Formula II:
Formula II
49. The compound of any one of the claims 42-45, wherein L is -(CH2),
50. The compound of any one of claims 42-45 and 49, wherein A is purinyl, L2 is a direct bond and B is phenyl.
51. The compound of any one of the claims 42-45 and 49-50, wherein the compound is a compound of Formula III:
Formula III
52. The compound of claim 49, wherein A is bipyridyl, L2 is -(CH2)P-, B is phenyl.
53. The compound of claim 52, wherein A is 4,4 '-bipyridyl, and L and L2 are bound to A via the nitrogen atoms of the bipyridyl moiety.
54. The compound of any one of the claims 42-45, 49 and 52-53, wherein the compound is a compound of Formula IV:
Formula IV wherein X" is chloride, bromide, iodide or fluoride.
55. The compound of any one of claim 47748 and 50-51, wherein the thiol substituent is in the 2- or 6-position of the purine ring.
56. The compound of any one of claims 47-48 and 50-55, wherein the boronic acid substituent is in the m- or p-position of the phenyl ring.
57. The compound of any one of claims 42-56, wherein the compound is a halogen salt.
Formula V wherein X" is chloride, bromide, iodide or fluoride, and D is selected from the group consisting of-(CH2)p-, -(0-CH2-CH2)n-, -(CH2-CH2-0)n-, -(CH2-CH2-0)n-(CH2)m- and
-(0-CH2-CH2)n-(CH2)m-5 wherein p is an integer from 1 to 20, n is an integer from 1 to 10 and m is an integer from 1 to 5.
59. The compound of claim 58, wherein the compound is a compound of
Formula VI
Formula VI wherein X" is chloride, bromide, iodide or fluoride, and n is an integer from 1 to 10.
60. The compound of claim 58 or 59, wherein the pyridyl rings are connected as to form a 3,4'-, 4,3'-, 3,3'- or 4,4'-bipyridyl structure.
61. The compound of any one of claims 58-60, wherein the bipyridyl benzyl boronic acid moiety is selected from the group consisting of:
N,N'-Bis-(benzyl-3-boronic acid)-[3,4']bipyridinium Dibromide (J,4'-m-BBV); N,N'-Bis-(benzyl-2-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-o-BBV); N,N'-Bis-(benzyl-4-boronic acid)-[3,4']bipyridinium Dibromide (3,4'-jp-BBV);
N,N'-Bis-(benzyl-3 -boronic acid)-[3,3']bipyridinium Dibromide (3,3'-m-BBV); N,N'-Bis-(benzyl-2-boronic acid)-[3,3']bipyridinium Dibromide (3,3'-o-BBV); N,N'-Bis-(benzyl-4-boronic acid)-[3,3']bipyridinium Dibromide (3,3'- ?-BBV); N,N'-Bis-(benzyl-3-boronic acid)-[4,4']bipyridinium Dibromide (4,4'-m-BBV); N,N'-Bis-(benzyl-2-boronic acid)-[ 4']bipyridinium Dibromide (4,4'-o-BBV); and
N,N'-Bis-(benzyl-4-boronic acid)-[4,4']bipyridinium Dibromide (4,4'- ?-BBV);
62. The compound of claim 61 , wherein the -C(0)-S-(CH2-CH2-0)n-CH2-SH or the -C(0)-S-D-SH group is in the m-position relative to the nitrogen atom of the pyridine ring.
63. The method of any one of claims 1-23, wherein the compound is a compound of any one of claims 42-62.
64. The biosensor of any one of claims 24-41, wherein the compound is a compound of any one of claims 42-62.
65. An optical fiber comprising a biosensor according to any one of claims 24- 41 and 64.
66. Use of the compound of any one of claims 42-62 as a monosaccharide or a- hydroxy acid receptor.
67. Use of the biosensor of any one of claims 24-41 and 64 or the optical fiber of claim 65 for the detection of an analyte.
68. The use of claim 67, wherein the detection is in vivo.
69. The use of claim 67, wherein the detection is in vitro.
70. The use of any one of claims 67-69, wherein the analyte is monosaccharide or an a-hydroxy acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG200907194 | 2009-10-29 | ||
SG200907194-5 | 2009-10-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011053247A1 true WO2011053247A1 (en) | 2011-05-05 |
WO2011053247A8 WO2011053247A8 (en) | 2011-11-03 |
Family
ID=43922356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2010/000383 WO2011053247A1 (en) | 2009-10-29 | 2010-10-08 | Method for the detection of an analyte by surface enhanced raman spectroscopy (sers) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011053247A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102954956A (en) * | 2011-08-25 | 2013-03-06 | 福州高意光学有限公司 | Enhanced Raman spectroscopy test piece device and test piece manufacturing method |
WO2014103220A1 (en) * | 2012-12-27 | 2014-07-03 | パナソニック株式会社 | Method for detecting test substance, and detection system |
WO2014196169A1 (en) * | 2013-06-04 | 2014-12-11 | パナソニック株式会社 | Sensor chip, detection method and detection device |
RU2542427C2 (en) * | 2013-03-12 | 2015-02-20 | Федеральное государственное бюджетное учреждение науки Институт теплофизики им. С.С. Кутателадзе Сибирского отделения Российской академии наук (ИТ СО РАН) | Non-invasive laser nano-diagnostic technique for oncologic diseases |
WO2015038077A1 (en) * | 2013-09-16 | 2015-03-19 | Agency For Science, Technology And Research | Method of detecting hydrogen peroxide |
CN105424677A (en) * | 2015-12-02 | 2016-03-23 | 公安部上海消防研究所 | Method for detecting residual organics on fire scene based on surface enhancing raman spectrum |
CN106232606A (en) * | 2014-04-23 | 2016-12-14 | 血糖测试仪股份有限公司 | For measuring the non-enzymatic electrochemical sensor of analyte |
JP2017173313A (en) * | 2016-03-18 | 2017-09-28 | 日機装株式会社 | Component analyzer |
US9921163B2 (en) | 2013-02-15 | 2018-03-20 | Imec Vzw | Method and device for detecting analytes |
CN108072639A (en) * | 2016-11-10 | 2018-05-25 | 中国科学院长春光学精密机械与物理研究所 | A kind of detection method of glucose |
CN110455775A (en) * | 2019-09-11 | 2019-11-15 | 重庆大学 | Super hydrophobic surface for Surface enhanced Raman spectroscopy detection enhances substrate |
CN114235773A (en) * | 2020-09-09 | 2022-03-25 | 南京大学 | Raman imaging method for dynamically monitoring cell membrane repairing process |
US12029744B2 (en) | 2020-04-10 | 2024-07-09 | Riboscience Llc | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103712970B (en) * | 2013-12-30 | 2017-02-01 | 青蛙王子(中国)日化有限公司 | Method for detecting content of dioxane in children cosmetics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050164A1 (en) * | 2004-10-29 | 2006-05-11 | The University Of Akron | Analysis for glucose products using pyridinylboronic acid |
WO2007067743A2 (en) * | 2005-12-07 | 2007-06-14 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts-ii |
-
2010
- 2010-10-08 WO PCT/SG2010/000383 patent/WO2011053247A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050164A1 (en) * | 2004-10-29 | 2006-05-11 | The University Of Akron | Analysis for glucose products using pyridinylboronic acid |
WO2007067743A2 (en) * | 2005-12-07 | 2007-06-14 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts-ii |
Non-Patent Citations (3)
Title |
---|
CHEN ET AL.: "Formation and Characterization of Self-Assembled Phenylboronic Acid Derivative Monolayers toward Developing Monosaccharide Sensing-Interface", SENSORS, vol. 7, 2007, pages 1480 - 1495 * |
GAMSEY ET AL.: "Boronic Acid-Based Bipyridinium Salts as Tunable Receptors for Monosaccharides and r-Hydroxycarboxylates", J. AM. CHEM. SOC., vol. 129, 2007, pages 1278 - 1286 * |
YONZON ET AL.: "A Glucose Biosensor Based on Surface-Enhanced Raman Scattering: Improved Partition Layer, Temporal Stability, Reversibility, and Resistance to Serum Protein Interference", ANAL. CHERN., vol. 76, 2004, pages 78 - 85 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102954956A (en) * | 2011-08-25 | 2013-03-06 | 福州高意光学有限公司 | Enhanced Raman spectroscopy test piece device and test piece manufacturing method |
WO2014103220A1 (en) * | 2012-12-27 | 2014-07-03 | パナソニック株式会社 | Method for detecting test substance, and detection system |
US9964491B2 (en) | 2012-12-27 | 2018-05-08 | Panasonic Corporation | Method and detection system for detecting an analyte |
US9921163B2 (en) | 2013-02-15 | 2018-03-20 | Imec Vzw | Method and device for detecting analytes |
RU2542427C2 (en) * | 2013-03-12 | 2015-02-20 | Федеральное государственное бюджетное учреждение науки Институт теплофизики им. С.С. Кутателадзе Сибирского отделения Российской академии наук (ИТ СО РАН) | Non-invasive laser nano-diagnostic technique for oncologic diseases |
US9610033B2 (en) | 2013-06-04 | 2017-04-04 | Panasonic Corporation | Sensor chip, detection method, and detection apparatus |
WO2014196169A1 (en) * | 2013-06-04 | 2014-12-11 | パナソニック株式会社 | Sensor chip, detection method and detection device |
JP5889487B2 (en) * | 2013-06-04 | 2016-03-22 | パナソニック株式会社 | Sensor chip, detection method and detection apparatus |
WO2015038077A1 (en) * | 2013-09-16 | 2015-03-19 | Agency For Science, Technology And Research | Method of detecting hydrogen peroxide |
US9915670B2 (en) | 2013-09-16 | 2018-03-13 | Nanyang Technological University | Method of detecting hydrogen peroxide |
JP2017521358A (en) * | 2014-04-23 | 2017-08-03 | グルコベーション, インコーポレーテッドGlucovation, Inc. | Non-enzymatic electrochemical sensor for measuring analytes |
JP2022101652A (en) * | 2014-04-23 | 2022-07-06 | テルモ株式会社 | Non-enzymatic electrochemical sensor for measuring analytes |
EP3134419A4 (en) * | 2014-04-23 | 2017-12-20 | Glucovation, Inc. | Non-enzymatic electrochemical sensor for measuring analytes |
US10761053B2 (en) | 2014-04-23 | 2020-09-01 | Terumo Kabushiki Kaisha | Non-enzymatic electrochemical sensor for measuring analytes |
CN106232606A (en) * | 2014-04-23 | 2016-12-14 | 血糖测试仪股份有限公司 | For measuring the non-enzymatic electrochemical sensor of analyte |
EP3498718A1 (en) * | 2014-04-23 | 2019-06-19 | Terumo Kabushiki Kaisha | Non-enzymatic electrochemical sensor for measuring analytes |
JP2019164139A (en) * | 2014-04-23 | 2019-09-26 | テルモ株式会社 | Non-enzymatic electrochemical sensor for measuring analytes |
CN105424677A (en) * | 2015-12-02 | 2016-03-23 | 公安部上海消防研究所 | Method for detecting residual organics on fire scene based on surface enhancing raman spectrum |
CN105424677B (en) * | 2015-12-02 | 2018-01-12 | 公安部上海消防研究所 | Method based on SERS detection scene of fire residual organic matter |
JP2017173313A (en) * | 2016-03-18 | 2017-09-28 | 日機装株式会社 | Component analyzer |
CN108072639A (en) * | 2016-11-10 | 2018-05-25 | 中国科学院长春光学精密机械与物理研究所 | A kind of detection method of glucose |
CN110455775A (en) * | 2019-09-11 | 2019-11-15 | 重庆大学 | Super hydrophobic surface for Surface enhanced Raman spectroscopy detection enhances substrate |
CN110455775B (en) * | 2019-09-11 | 2023-12-01 | 重庆大学 | Super-hydrophobic surface-enhanced substrate for surface-enhanced Raman spectrum detection |
US12029744B2 (en) | 2020-04-10 | 2024-07-09 | Riboscience Llc | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
CN114235773A (en) * | 2020-09-09 | 2022-03-25 | 南京大学 | Raman imaging method for dynamically monitoring cell membrane repairing process |
CN114235773B (en) * | 2020-09-09 | 2024-02-09 | 南京大学 | Raman imaging method for dynamic monitoring of cell membrane repair process |
Also Published As
Publication number | Publication date |
---|---|
WO2011053247A8 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011053247A1 (en) | Method for the detection of an analyte by surface enhanced raman spectroscopy (sers) | |
Zhang et al. | Long-lived emissive probes for time-resolved photoluminescence bioimaging and biosensing | |
Zhao et al. | Target-activated modulation of dual-color and two-photon fluorescence of graphene quantum dots for in vivo imaging of hydrogen peroxide | |
Guo et al. | Rhodamine-functionalized graphene quantum dots for detection of Fe3+ in cancer stem cells | |
JP5476638B2 (en) | Optical determination of glucose using boronic acid adduct-II (Bronic Acid Addacts-II) | |
Aslan et al. | Nanogold plasmon resonance-based glucose sensing. 2. Wavelength-ratiometric resonance light scattering | |
Cheng et al. | A new approach to design ratiometric fluorescent probe for mercury (II) based on the Hg2+-promoted deprotection of thioacetals | |
Cui et al. | Serial silver clusters biomineralized by one peptide | |
Liu et al. | Development of upconversion luminescent probe for ratiometric sensing and bioimaging of hydrogen sulfide | |
Li et al. | FRET-based biofriendly Apo-GO x-modified gold nanoprobe for specific and sensitive glucose sensing and cellular imaging | |
Ng | Carbon dots as optical nanoprobes for biosensors | |
JP6081152B2 (en) | Fluorescent compounds comprising tetraphenylethene derivatives | |
Soleymani | Advanced materials for optical sensing and biosensing of neurotransmitters | |
Cerretani et al. | Switchable dual-emissive DNA-stabilized silver nanoclusters | |
Verma et al. | Naphthalimide-based DNA-coupled hybrid assembly for sensing Dipicolinic acid: a biomarker for Bacillus anthracis spores | |
Lu et al. | Enhancing hydrophilicity of photoacoustic probes for effective ratiometric imaging of hydrogen peroxide | |
Zhong et al. | A rational designed bioorthogonal surface-enhanced Raman scattering nanoprobe for quantitatively visualizing endogenous hydrogen sulfide in single living cells | |
Cao et al. | Highly water-soluble monoboronic acid probes that show optical sensitivity to glucose based on 4-sulfo-1, 8-naphthalic anhydride | |
US20170266321A1 (en) | Anthracenyl-tetralactam macrocycles and their use in detecting a target saccharide | |
Fan et al. | Aggregation-induced emission effect within peroxyoxalate-loaded mesoporous silica nanoparticles for efficient harvest of chemiluminescence energy in aqueous solutions | |
Ngo et al. | Raman thermometry nanopipettes in cancer photothermal therapy | |
Olmon et al. | Using metal complex reduced states to monitor the oxidation of DNA | |
Liu et al. | All-in-one luminescent lanthanide coordination polymer nanoprobe for facile detection of protein kinase activity | |
CN114195774A (en) | Photosensitizer with hypochlorous acid activated fluorescence and mitochondrion targeting functions and preparation method and application thereof | |
Dey et al. | Surface engineered PLGA nanoparticle for threshold responsive glucose monitoring and “self-programmed” insulin delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10827251 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10827251 Country of ref document: EP Kind code of ref document: A1 |